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ABSTRACT 
Patellar tendinosis is a common chronic tendon disorder with anterior knee 
pain associated with tenderness at the proximal part of the patellar tendon. There is 
no defined and consistent rationale in the current management due to unknown 
pathogenesis and etiology. 
Histopathologic studies have characterized patellar tendinosis with 
hypercellularity, disorganization and loosening of collagen fibrils, and lack of 
inflammatory cell infiltration even though there was pain and swelling of affected 
tendon. However, the cause of these alterations is not known. 
In this study, hypercellularity and disorganization and loosening of collagen 
fibrils as well as the possible causes for pain and swelling were further studied on 
human patellar tendinosis tissues and compared with healthy controls. The 
expression of growth factors had also been studied to elucidate their roles in 
contributing to these histopathological changes. 
Surgical samples from 11 patients fulfilling criteria of patellar tendinosis, and 
from 12 sex and age matched controls with healthy patellar tendons operated on for 
anterior cruciate ligament reconstruction were analyzed with immunohistochemistry. 
Immunohistochemical results were analyzed by computer assisted microscopy. 
Results from characterization on hypercellularity showed that an increased 
cellularity was observed in tendinosis tissues compared with controls, associated 
with a higher proliferative index, by detecting the expression of the proliferating cell 
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nuclear antigen (PCNA). This indicated that increased cell number in patellar 
tendinosis is caused by increased cell proliferation. 
To further characterize disorganization and loosening of collagen fibrils, the 
expressions of heat shock protein47 (hsp47), a collagen-specific stress protein, and 
procollagen type I was detected to access the synthesis of collagen. Results showed 
that the expressions of hsp47 were significantly higher in patellar tendinosis than in 
healthy controls, indicating the presence of stressful factors and an increased need of 
the synthesis of collagen. But the difference of expression for procollagen type 1 was 
not significant, indicating a limited production of collagen. An increased expression 
level of matrix metalloproteinase 1 (MMPl)，one of the extracellular collagenases, 
and decreased level of tissue inhibitors of metalloproteinase 1 (TIMPl), one of its 
endogenous inhibitor, concededly demonstrated a condition favouring collagen 
degradation in patellar tendinosis tissues. Furthermore, in situ zymography also 
showed that there was increased gelatinolytic activity in patellar tendinosis. 
Therefore a disturbed collagen synthesis and an augmented extracellular matrix 
degradation in patellar tendinosis were indicated. 
Cyclo-oxygenase 2 (COX-2), which is the rate-limiting enzyme for the 
synthesis of pro-inflammatory prostaglandins, was detected by 
immunohistochemistry to explain the pain and swelling of tendinosis patellar tendon. 
Result showed that the expression of COX-2 was significantly higher in tendinosis 
tissues with suggesting a trace of localized inflammatory response even though there 
was no inflammatory cell infiltration, and possible involvement of inflammatory 
mediators in the development and pathogenesis of patellar tendinosis. 
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The histopathological alterations may result from the change of growth 
factors and receptors expression. Transforming growth factor p (TGF(3) and platelet-
derived growth factor beta (PDGFBB), which are the two growth factors that have 
broad effects on the development and repair processes of tendons, were detected their 
expression level by immnohistochemistry. One of the growth factors receptor, 
platelet-derived growth factor receptor beta (PDGFRP), was also detected to evaluate 
whether there is a change in the receptor level. Results showed that the expression 
level of TGppi and PDGFRP was significantly higher in patellar tendinosis than in 
healthy controls. There was no significant difference between the expression level of 
PDGFBB in patellar tendinosis and healthy controls. Our results implied that the 
alteration in the expression of growth factors and their receptor might play an 
important role in the pathogenesis of patellar tendinosis. 
In conclusion, the current study on patellar tendinosis showed 
hypercellularity is caused by increased cell proliferation and there were a disturbed 
collagen synthesis and an augmented extracellular matrix degradation in patellar 
tendinosis. An increased COX-2 may contribute to pain and swelling and implied an 
inflammatory response exists. The alterations of growth factors and their receptor 
expression in patellar tendinosis might contribute to these changes. 
Future studies should focus on the growth factors pathway in the 
pathogenesis of patellar tendinosis. It would be helpful to perform a clinical study 
and to create an appropriate animal model in order to study the etiology and to 









































Question 1: Why study patellar tendinosis? 
i  
Patellar tendinosis, presenting with anterior knee pain associated with 
tenderness at the proximal part of patellar tendon, is a common chronic tendon 
disorder. There is no defined and consistent rationale in the current management 
due to its unknown pathogenesis and etiology. 
y _  
Question 2: How to study patellar tendinosis? 
一 ^ 1) Human samples 
1 r  
Surgical samples were taken from 11 patients fulfilling criteria of patellar 
tendinosis. 
The controls were 12 patients who underwent reconstruction of the 
anterior cruciate ligaments, using the patellar tendon as healthy autograft 
^ 2) Histological characteristics of human samples 
1 r  
Histological characterization on human tissues showed that all patellar 
tendinosis tissues, to various extents, exhibited hypercellularity, 
disorganization and loosening of collagen matrix, and no inflammatory 
cells infiltration. No histological abnormalities were found in the healthy 
patellar tendon controls. 
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Question 3: HvDercellularitv results from increased cell proliferation? 
Y  
Methods & Results: 
• Detection expression of PCNA by immunohistochemical staining. 
• An increased cellularity and a higher proliferative index were 
observed in patellar tendinosis tissues compared with controls. 
vi 
Answer: 
YES. Hypercellularity in patellar tendinosis may be caused 
by increased cell proliferation  
] r  
Contribution: 
1，CG Rolf, SC Fu, A Pau, W Wang, P Chan, KM Chan. Increased cell proliferation and 
associated expression of PDGFRD causing hypercellularity in patella tendinosis. Third 
Scientific Congress of Chinese Speaking Orthopaedic Society. Oct.2000. 
2，CG Rolf, SC Fu, A Pau, W Wang, P Chan, KM Chan. Increased cell proliferation and 
associated expression of PDGFRD causing hypercellularity in patella tendinosis. 
Rheumatology. (In printing). 
Question 4: Is there disorganization and loosening of collagen fibrils 
associated with disturbance of collagen metabolism in patellar tendinosis? 
i  
Methods & Results: 
• To access collagen synthesis by detection of expression of procollagen 
Type I and hsp47; To access collagen degradation by detection of 
expression of MMPl and TIMPl, by immunohistochemical staining. 
• The expression level of hsp47 was significantly higher in patellar 
tendinosis indicating the presence of stressful factors and an increased 
need of collagen synthesis; but the difference of expression for 
procollagen type 1 was not significant. 
• An increased expression level of MMPl and decreased expression 
level of TIMPl were demonstrated in patellar tendinosis. An increased 
gelatinolytic activity had also been demonstrated in patellar tendinosis 
by in situ zymography. 
i  
Answer: 
YES. Disturbed collagen synthesis and an augmented 
collagen degradation in patellar tendinosis are seen. 
i  
Contribution: 
1，Wang Wen, Barbara Chan, Fu Sai Chuen, Chan Kai Ming, Rolf Christen The Expression of Heat-
Shock Protein 47 and Procollagen Type I in Tendinosis Patellar Tendon. The Annual Congress, The 
Hong Kong Orthopaedic Association. Nov. 1999 
2, Barbara P Chan, SC Fu, W Wang, KM Chan, CG Rolf. Immunohistochemical evidence on increased 
expression of heat shock protein 47 (hsp47) and matrix metalloproteinase 1 (MMPl) in patellar 
tendinosis. To be submitted. 
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Question 5: 
Why is there pain and swelling without inflammatory cell 
infiltration? 
y  
Methods & Results: 
• Detection of expression of COX-2, which is a rate-limiting enzyme for 
the synthesis of prostaglandins, by immunohistochemical staining. 
• The expression of COX-2 was significantly higher in tendinosis 
tissues in contrast to healthy controls 
3 r  
Answer: 
An increased COX-2 results in a greater production of prostaglandins, that 
might lead to pain and swelling. It also implied an inflammatory response 
exists and in the pathogenesis of patellar tendinosis. 
^ r  
Contribution: 
1，Fu SC, Wang W, Pau HM, Rolf CG, Chan KM. Increased expression of Cyclo-oxygenase-2 (COX-2) 
and Transforming Growth Factor • 1 (TGF-pl) in patellar tendinosis. Ready to Submit. 
Question 6: 
Are there alterations of growth factors and receptors expression in 
patellar tendinosis? Since the histopathological alterations may 
result from the change of growth factors and receptors expression. 
] r  
Methods & Results: 
• Detection expression of PDGFBB, TGppi and PDGFR(3 by 
immunohistochemical staining. Since these growth factors have been 
broadly involved in the development and repair processes of tendon. 
• The expression of TGF(3l and PDGFRP was significantly higher in 
tendinosis tissues. While the expression of PDGFBB was not difference in 
patellar tendinosis in contrast to healthy controls. 
viii 
] r  
Answer: 
YES. In patellar tendinosis there was a change in the expression 
of growth factors. 
Conclusion: 
The current study has further studied patellar tendinosis in the aspects of hypercellularity, 
disorganization and loosening of collagen fibrils, which are the possible causes for pain and 
swelling as well as the expression of growth factors. Results showed that hypercellularity is 
caused by increased cell proliferation and there is disturbed collagen synthesis and an augmented 
extracellular matrix degradation in patellar tendinosis. An increased COX-2 may contribute to 
pain and swelling and suggest that an early inflammatory response exits. The alterations of 
growth factors and their receptor expression in patellar tendinosis might contribute to these 
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1.1 PATELLAR TENDINOSIS 
1.1.1 Introduction 
The term “Tendinosis，，，was first used by Puddu implying tendon degeneration 
without clinical or histological signs of intratendinous inflammation (Puddu et al., 
1976). It is a common chronic tendon disorder with unknown pathogenesis and etiology 
(Galloway et al” 1992; Leadbetter, 1992; Astrom et al., 1995; Rolf et al., 1997; Movin et 
al., 1997; Rolf, 1998; Movin et al, 1998; Khan et al., 1999). The clinical manifestation 
is longstanding localized and activity related pain and swelling, similar entities being 
described in the patellar tendon (Feretti et al., 1983; Duri et al., 1999), the Achilles 
tendon (Galloway et al., 1992), the rotator cuff of the shoulder as well as extensor carpi 
radialis brevis tendon (Nirschl et al., 1992; Wolf et al” 1992; Kraushaar et al., 1999)，but 
also other locations (Khan et al., 1999). Previous literature is not consistent in the 
terminology and definition of tendinosis (Maffulli, 1998; Maffulli et al” 1999). It is 
sometimes labeled as chronic "tendinitis", although there is no infiltration of 
inflammatory cells (Anonymous, 1992; Almekinders et al., 1998). From etiologic point 
of view, tendinosis is often labeled as an overuse injury occurs as a result of work-
induced or sports-induced repetitive overloading of the muscle-tendon unit, although it 
occurs in many patients who do not perform vigorous physical activity (Roels et al” 
1978; Stem et al., 1990; Rolf et al” 1997). Some authors propose a degenerative nature 
to the disorder, although tendinosis can be found also in young people (Rolf et al., 
1998). , 
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Histopathologic studies on tendinosis tissues characteristically demonstrate 
hypercellularity, hypervascularity, lack of inflammatory infiltrates and disorganization 
and loosening of collagen fibrils (Astrom et al.，1995; Rolf et al., 1997; Khan et al.， 
1999). Another obvious alteration is an increase of glycosaminoglycan content in the 
extracellular matrix (Movin et al., 1997). It is unclear whether sub-stages of tendinosis 
exist and whether it is an ongoing process or an end stage. Consequently, there is no 
defined and consistent rationale in the current management on tendinosis (Sandmeier et 
al., 1997; Khan et al., 1999). 
Patellar tendinosis, commonly called "jumper's knee", is very common in 
orthopaedic sport medicine (Blazina et al., 1973; Fredberg et al., 1999). The patient 
with patellar tendinosis was anterior knee pain associated with tenderness at the 
proximal part of the patellar tendon. In patellar tendinosis, ultrasound (US) examination 
and magnetic resonance imaging (MRI) reveal abnormal signals at the proximal part of 
the patellar tendon (Khan et al., 1996). However, in daily clinical practice, jumper's 
knee often labeled as chronic patellar "tendinitis", a condition in which the tendon tissue 
exhibits an inflammation, or other names such as "patellar tendinopathy", "patellar 
tendinosis", "patellar tendinitis，，，"patellar tendon disorder，，，“ insertion tendinitis of the 
patellar tendon", and "partial rupture of the patellar tendon" (Jozsa, 1997; Popp et al., 
1997; Powell et al, 1998). A lack of systematic characterization illustrates the little we 
know about the pathogenesis and etiology of patellar tendinosis, leading to no effective 
treatment strategy. 
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1.1.2 Epidemiology of Patellar Tendinosis 
The true incidence of patellar tendinosis is not known since previous literature is 
not consistent in the terminology and definition. It has been reported that one-fourth of 
all athletes treated for a knee disorder were diagnosed with patellar tendinitis (Ferretti et 
al.，1986; Kujala et al.，1986). Jumper's knee is most commonly seen in athletes from 
the sports of basketball, volleyball, football, soccer, high jump, long jump, badminton, 
and running (Blazina ME, 1973; Gecha et al., 1988; Kujala et al, 1989; Molnar et al., 
1993; Puddu G 1993; Lian et al., 1996). The gender ratio of patients seems to suggest 
that patellar tendinosis is more prevalent in males than in females, but no controlled 
studies support this suggestion (Ferretti et al., 1990; Khan et al., 1997). There are no 
controlled studies, which show the relationship between the age, race, activity level and 
the incidence of patellar tendinosis. 
1.1.3 Etiology of Patellar Tendinosis 
The etiology of patellar tendinosis is not known. Both extrinsic factors and 
intrinsic factors have been proposed (Kujala et al., 1986). Extrinsic factors including 
overuse and disuse (Jarvinen M et al 1997) have been discussed to provoke the 
condition. Patellar tendinosis has been found among elite athletes as well as in 
recreational athletes (Rolf & Movin 1997), but interestingly also in patients with no 
relation to vigorous physical activities or "disuse" (Rolf et al., 1997). Some authors 
propose a degenerative nature to the disorder, although tendinosis can be found also in 
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young people (Matsumato et al., 1999). Intrinsic factors such as age (Riley et al, 1994), 
restricted blood flow and local hypoxia (Jarvinen M et al., 1997)，have also been 
suggested to be involved. Other extrinsic factors such as training errors, environmental 
malconditions, poor equipment, ineffective rules, as well as intrinsic factors such as 
malalignments of extremities (Carpenter et al., 1998; Allen et al., 1999), muscle 
weakness/imbalance, decreased flexibility (Faletti et al., 1998)，have been also 
concerned the predisposing factors or risk factors to patellar tendinosis (Jozsa, 1997). 
1.1.4 Manifestations of Patellar Tendinosis 
The clinical manifestation of patellar tendinosis is longstanding localized and 
activity related pain and swelling over the proximal part of the patellar tendon. The onset 
of symptoms is often insidious. Initially, patients with patellar tendinosis will complain 
of a dull ache in the anterior knee after strenuous activity. Patients also commonly 
complain of activity-related pain (Ferritti et al., 1985). 
Physical examination shows that the key finding in patellar tendinosis is the 
tenderness at the inferior pole of the patella or in the main body of the tendon. When the 
knee is flexed to 90 degree, the proximal part of patellar tendon appears to have a little 
bulge and an unclear marginal mass can usually be palpated. A remarkable feature of 
patellar tendinosis is that there are generally few classical signs of soft tissue 
inflammation. 
� 
1.1.5 Imaging Examination on Patellar Tendinosis 
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MRI and US are the imaging modalities commonly chosen in patients with 
patellar tendinosis for its advantage of sensitivity for soft tissue (Mourad et al.，1988; 
Khan et aL, 1996). 
Ultrasonographic appearance of patellar tendinosis shows that there are the 
characteristic sonographic hypoechogenic regions around the proximal part of patellar 
tendon (Fritschy et al” 1988; Cook et al., 1998). The regions may represent fluid 
accumulation due to increase of the hydrophilic proteoglycans in the extra-cellular 
matrix (Myllymaki et al., 1990; Movin et aL, 1997; Kiss et al, 1998). (Fig. 1.2) 
On MRI examination of patellar tendinosis, the abnormal patellar tendon 
contains an oval or round area of high signal intensity on T1 and T2 weighted images or 
a focal zone of high signal intensity in the deep layers of the proximal part of patellar 
tendon (Fig. 1.3). Tendons with patellar tendinosis have increased anteroposterior 
diameter in the affected region (Bodne et al., 1988). Movin et al. demonstrated that Tl-
weighted images following gadolinium contrast medium enhancement proved to be the 
best method by which to visualize intratendinous signal abnormality. It may be due to a 
high level of extracellular glycosaminoglycans, which are highly-fix negatively-charged 
macromolecules with extreme water-retaining capacity and which may have contributed 
to the enhancement by the gadolinium contrast agent ( Movin et al 1998). Movin et al 
also demonstrated that MRI revealed greater sensitivity in demonstrating intra-tendinous 
pathology than the ultrasound; this was documented by the larger size of the 
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corresponding lesion and that the pathology was occurring in areas that were considered 
normal by ultrasonography (Movin et al 1998). 
1.1.6 Clinical Diagnosis of Patellar Tendinosis 
The clinical diagnosis of patellar tendinosis is based on patients' subjective 
reports of pain, and the combination of the key physical and image findings as 
mentioned before. The main differential diagnosis is with the patellofemoral syndrome, 
and the two conditions can coexist (Colosimo et al., 1990). 
1.1.7 Management of Patellar Tendinosis 
There is no defined and consistent rationale in the current management of 
patellar tendinosis due to unknown pathophysiology. Treatments for patellar tendinosis 
include conservative and surgical management, which has been more empirical (Cook et 
al., 1997). 
Many conservative treatments have been proposed including correction of 
predisposing factors, relative or absolute rest, stretching and strengthening, physical 
therapy modalities, ice, massage, non-steroidal anti-inflammatory medication, 
corticosteroids by injection etc (Kibler et al., 1992; EI Hawary et al., 1997). However, 
there are no standard measurements and well-designed controlled studies to assess the 
efficacy of the treatments. NSAIDs may be the most widely used medication to treat 
patellar tendinosis. However, from a theoretical point of view, one would predict that the 
. 6 
anti-inflammatory action of NSAIDs would have no therapeutic effect in tendinosis, and 
the analgesic effect of NSAIDs may make patients to ignore early symptoms, further 
damage tendon and, thus, delay definitive healing. Furthermore, some treatments are 
even not appropriate for tendinosis - a non-inflammatory condition, such the usage of 
corticosteroids by injection. It is suggested that corticosteroid injection into tendon 
tissue make cell death, tendon atrophy, and inhibit collagen synthesis as well as decrease 
load to failure (Almekinders et al., 1995; Smith et al., 1999). 
Surgical treatment is generally performed when the patient has not improved 
with at least six months of conservative management (Binfield et al., 1997). The aim of 
surgery for tendinosis is to remove the pathological tissue and to promote the tendon 
healing (Orava et al., 1986). A variety of surgical treatment for patellar tendinosis has 
been described (Binfield PM 1997). These include drilling of the inferior pole of the 
patella, resection of the tibia attachment of the patellar tendon with realignment, 
longitudinal tenotomy/tenoplasty of the tendon, percutaneous needling and arthroscopic 
assisted decompression of the tendon etc ( Karlsson et al., 1991; Verheyden et al., 1997; 
Johnson et al., 1998). The outcome of the surgery varies for different methods to be used 
and has not been evaluated scientifically (Nelen et al., 1989; Pierets et al” 1999). 
1.2 ANATOMY AND HISTOLOGY OF PATELLAR TENDON 
A complete understanding of the anatomy and histology of healthy patellar 
tendon facilitates further histopathological studies on patellar tendinosis. 
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The patellar tendon, the extension of the common tendon of insertion of the 
quadriceps femoris muscle, takes its origin from the apex or distal pole of the patella and 
inserts distally into the tibial tuberosity (Fig. 1.1). In adult it is about 2.5 to 4.0 cm wide 
and 4 to 5 mm thick. The average length of the patellar tendon is 4.3 to 4.6 cm (range, 
2.0 to 6.5 cm)(Insall, 1984; Reider et al., 1981). Macroscopically patellar tendons appear 
glistening, stringy, and white. The patellar tendon is surrounded by two layers of tendon 
sheath. The outer layer is the fibrotic (ligamentous) sheath and the inner layer is the 
synovial sheath that consists of thin visceral and parietal sheaths (Jozsa, 1997). Their 
main function is to minimize the friction between the tendon and its surrounding 
structures. The main contributors of the blood supply to the patellar tendon are the 
medial inferior genicular, lateral superior genicular, lateral inferior genicular, and the 
anterior tibial recurrent artery (Scapinelli, 1968). The neurologic input to the patellar 
tendon is formed by communications between the terminal branches of the lateral, 
intermediate, and medial cutaneous nerves of the thigh, as well as the infrapatellar 
j 
branch of the saphenous nerve. The patellar tendon as part of the extensor mechanism of [ 
the knee contributes to stability and movement of the knee as well as the patellofemoral 
joint. 
Microscopically, healthy patellar tendon consists of dense, clearly defined, 
parallel and slightly wavy collagen bundles, which show a characteristic reflective 
appearance under polarized microscopy. Between the collagen bundles there is a fairly 
even, sparse distribution of cells with thin, wavy nuclei. There is an absence of stainable 
proteoglycans in the extra-cellular matrix and no cell proliferation (0，Brien, 1992). 
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Tendon is supplied by a network of small arteries oriented parallel to the collagen fibres 
in the endotenon (Astrom et al., 1995; Jozsa, 1997; Khan et al” 1999). 
1.3 STRUCTURES AND METABOLISM OF TENDON 
Although the morphology and function of tendons varies in their distribution, the 
basic structure and metabolism of tendons are the same (O'Brien et al., 1997). An 
understanding of the structure and metabolism of normal tendons will facilitate the 
understanding of the histopathological findings and the pathogenesis of patellar 
tendinosis (Leadbetter, 1992). On the other hand, once the tendon injured, the injured 
tendon go through a healing process. During the tendon healing process, there are a 
series of changes to the various components of tendon. So knowing what and how 
various components of tendon alter during the tendon healing process may help to 
understand the histopathological findings and the pathogenesis of patellar tendinosis. 
Also, this will benefit the planning of treatment and rehabilitation protocol for patients [ 
with patellar tendinosis. 
The basic elements of tendon can be divided into two major parts: one is the 
cellular components, another one is extra-cellular matrix. 
1.3.1 Tenocytes 
The tendon cells, also called tendon fibroblast or tenocyte, comprise about 90% 
to 95% of the cellular component of the tendon (Jozsa, 1997). The remainders, including 
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the chondrocytes at the pressure and insertion sites, the synovial cells of the tendon 
sheath on the tendon surface, and the vascular cells, such as capillary endothelial cells 
and smooth muscle cells of the arterioles in the endotenon and epitenon, are less than 
5% to 10% in the normal tendon (Banes et al., 1988). 
The cell-to-matrix ratio gradually decreases with aging, and also many other 
changes occur inside the tendon cells. The embryonic tendon has a very high cell to 
matrix ratio; the tendon fibroblasts have various shapes and sizes. In young individuals, 
a gradual decrease in the cell-to matrix ratio occurs and the tendon fibroblasts start to 
resemble each other and are spindle shaped. In adults, the cell-to-matrix ratio further 
decreases and the nucleus-to-cytoplasm ratio increases, the tenocytes become very flat 
and elongated (Jozsa, 1997; O'Brien et al., 1997). 
！ 
i 
Tenocytes sparingly distribute among collagen fibrils, synthesize both 
f 
proteoglycans and collagen (Jozsa, 1997; O'Brien et al., 1997). During early healing j: 
phase that is inflammatory phase, the cellular components within injured tendon are 
mainly the inflammatory cells. When the inflammation subsides, the tendon healing 
process proceeds to the proliferative phase. In this phase, the tendon fibroblasts are 
predominant within the tendon cellular components. The shape of the tendon fibroblasts 
appears more roundly and the endoplasmic reticulum of tendon fibroblasts enlarges. The 
tendon fibroblasts begin to produce collagen and matrix proteoglycans. This implies the 
tendon fibroblasts eagerly to repair the injury. Finally, during the maturation and 
remodeling phase, the cell-to-matrix ratio reduces gradually, the shape of tendon 
fibroblasts turn to flat and enlongated and the endoplasmic reticulum shrinks. The 
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tendon fibroblasts secrete more less collagen and matrix proteoglycans (Isabel et al., 
1985; Chan et al., 1997; Jozsa, 1997; O'Brien et al., 1997) 
1.3.2 Extracellular Matrix 
The extracellular matrix of tendons can be classified into three groups: (1) 
collagen and elastin fibers, (2) the ground substance, mainly the proteoglycan, (3) the 
inorganic components. Water is 60-80% of the total weight of tendons. However, 
collagen protein forms 65-80% of the dry weight tendons while the proteoglycans and 
glycoproteins account for less than 2% of the total dry weight of the tendon (Jozsa, 
1997). 
1.3.2.1 Collagen ij 
I, 
To date, more than 20 different types of collagen molecules have been found in 
the mammalian body and they can be divided into fibrillar and nonfibrillar collagen 
based on the supramolecular structures. Collagen type I，which is composed of two a l 
chains and one o l chain, is the major collagen in the tendon (>95%). Collagen type III， 
which may increase when the tendon is healing, comprises less than 5% of the total 
collagen content in the healthy tendons (O'Brien et al., 1997). 
Tenocytes are responsible for collagen synthesis in tendon. In response to injury 
and many other stresses, tenocytes synthesize procollagen type I (Satoh et al., 1996)， 
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which is the precursor for collagen type I fibres that are assembled in the extra-cellular 
milieu. Synthesis of procollagen often associates with the expression of heat shock 
protein 47 (hsp47), which is the only substrate-specific molecular chaperone assisting 
correct folding and assembling of procollagen (Nagata et aL, 1998). Hsp 47 belongs to 
heat shock protein family. Hsp47 is an inducible intracellular protein in response to 
stress. The cellular level of hsp47 augment under many stressful conditions such as 
injury, heat and toxins (Georgopolou et al., 1993; Gunther et al., 1994). Under stressful 
conditions, the maintenance of protein folding and hence proper protein functions is 
hampered, heat shock proteins including hsp47 serve to stabilize protein folding and 
sustain their functions. 
Remodeling of collagen is regulated through a balance between collagen 
I 
synthesis and degradation. Extracellular matrix degradation is mainly conferred by 
matrix metalloproteinases (MMPs)(Powell et aL, 1996; Murphy et al., 1999). These 
zinc-containing proteases are synthesized in forms of pro-enzymes and activated by i 
proteolytic cleavage (Murphy et al” 1999). The substrate specificity of MMPs is not 
clear-cut. Several categories of MMPs can be identified according to their proteolytic 
activity, for instance collagenases, stromeolysins, gelatinases, etc (Parks et al., 1998). In 
addition to the level of synthesis and pro-enzyme activation, activities of MMPs are 
regulated through a corresponding set of tissue inhibitors of metalloproteinases (TIMPs), 
such as TIMPl, which binds specifically to MMPl and render it inactive (Nagase et aL, 
1999). An increase in MMPs or decrease in TTMPs have been demonstrated to associate 
with collagen disturbances in tendons (Dalton et al., 1995) and ligament injuries 
(Spindler et al., 1996). 
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1.3.2.2 Proteoglycans 
Proteoglycans are the main component in the extra-cellular matrix. The 
proteoglycans are composed of a core •protein associated with four main 
glycosaminoglycans, dermatan sulphate, chondroitin sulphate, keratan sulphate and 
heparin sulphate. The glycosaminoglycans are linear polysaccharides that, with the 
exception of hyaluronic acid, are bound covalently to a protein core forming a 
proteoglycan. The proteoglycans is produced by the fibroblasts. They are constantly 
remodelled by the fibroblasts and the degraded enzymes such as proteoglycanase. The 
proteoglycans maintain the water within the tissues and are involved with intermolecular 
and cellular interactions. They surround the collagen fibres and have a high viscosity 
that provides a structural support and a medium for the diffusion of nutrients and gases 
i 
(Jozsa, 1997; O'Brien et al.，1997). 
! 
Remodeling and maturation of the extra-cellular matrix of tendons happens 
through the late phase of tendon healing processes. In these phases, there are an 
increased the new products of collagen and matrix proteoglycans, and these new 
products of collagen and matrix proteoglycans are immature and lack of organization 
and are therefore susceptible to destruction if further trauma or inflammation occurs. 
The restoration of matrix components parallels the increase in mechanical strength of 
injured soft tissue. Continuous deposition and degradation of collagen matrix persists for 
a long period of time to remodel the matrix. At last, the content of matrix proteoglycans 
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decreases and the new products of collagen mature (Isabel et al., 1985; Chan et al., 1997; 
Jozsa, 1997; O'Brien et al, 1997). 
1.4 Roles of Growth Factors in Tendon Healing and Repair 
Several growth factors have been shown to play an important role in regulating 
the development and maturation of normal tendons as well as the repair of injured 
tendons. Among these growth factors, platelet-derived growth factor beta (PDGFBB) and 
transforming growth factor-beta l(TGF(3l) are the factors that have been broadly studied 
and demonstrated to play important roles in inflammatory and tendon healing processes 
(Leadbetter, 1992; Merida-Velasco et al, 1997; Stone et al, 1999). 
1.4.1 Platelet-Derived Growth Factor 
Platelet-derived growth factor (PDGF) represents a family of related 
！ 
polypeptides that play a fundamental role in inflammation, neoplasia, and ‘ 
embryogenesis, as well as in wound healing. PDGF was so named because it was 
originally isolated from human platelets (Kohler et al., 1974). The molecule structure of 
PDGF consists of two disulphide-bonded polypeptide chains with about 60% amino acid 
homology, denoted A and B. There chains forms either homodimers or heterodimers. 
Thus, at least three functional isoforms, AB, BB, and AA, exist. They bind with 
different affinities to two receptor types, the a - and the P- receptor. PDGFRa binds both 
the A- and the B-chain while PDGFRp binds only the B-chain (Hart et al.’ 1988). 
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PDGF is now known to be produced by a number of cell types besides platelets 
and it has been found to be a mitogen for almost all mesenchymally-derived cells, i.e., 
connective tissue cells such as fibroblast, blood endothelia cells. PDGFBB have been 
shown to have promoting effects on tendon healing by attracting fibroblasts, and 
stimulates cell proliferation and collagen deposition. The capacity of PDGF to induce 
cell proliferation, as well as several other critical cell functions, depends on both the 
PDGF dimer present and the relative numbers of the two different PDGF receptor 
subunits on the responding cell (Hart et al., 1988; Barrett et al., 1996). Different cell 
types have different numbers of the two receptors subunits, for example, human 
fibroblasts contain at least ten-fold more p-subunits than a-subunits. Consequently, 
PDGFBB is about ten-fold more mitogenic for human fibroblasts than is PDGFAA 
(Smits et al., 1992). 
1.4.2 Transforming Growth Factor-beta 
TGFP，which is a superfamily of related polypeptides that mediate many key 
events in normal growth and development, is a 25 kDal homodimeric peptide which is 
expressed in many cell type of mammals as three highly homologous isoforms, TGF(3 1， 
2 and 3. They all bind to the same receptors and there are no major differences in 
biological activity among them (Benson, 1998). 
The initial characterization of the TGpps in 1983 was based on their ability to 
transform cells in vitro and subsequently more biological functions have been found. 
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TGppi, one of TGpps, have been showed that have mitogenic effects on fibroblasts and 
stimulate the chemotaxis of fibroblast (Chang et al., 1997). These effects underlie the 
action of TGFpl in tissue repair as well as in inflammation and fibrosis. Key to many of 
the effects of TGF(3l on tissue repair is its multiple actions on regulation of extracellular 
matrix metabolism. It is up-regulated in many pathological condition. Besides, it can 
also up-regulate the PDGPP receptor (Leadbetter, 1992; Marigo et al., 1994; Robbins et 
al, 1997). 
Both PDGFBB and TGppi have been shown to play very important roles in 
tendon healing processes. PDGFBB alone appears to be of limited value in accelerating 
tendon repair in vivo, but in combination with other growth factors such as TGppi is 
able to modulate the tendon healing process. An interaction between PDGFBB and 
TGppi may be important in tendon healing processes, but PDGFBB and TGppi enhance 
tissue repair activities by distinct mechanisms. Whereas TGppi transiently attracts 
I { 
fibroblasts into the wound and may stimulate collagen synthesis directly. PDGFBB is a 
more potent chemoattractant and stimulates to express endogenous growth factors, 
including TGppi which, in turn, stimulates new collagen synthesis and sustained 
enhancement of tendon healing over a more prolonged period of time (Leadbetter, 1992; 
Chan et al.’ 1997; Benson, 1998). 
1.5 Histopathology of Patellar Tendinosis 
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Basing on understanding the normal tendon structure, the histopathological 
alterations of patellar tendinosis can be better illustrated and compared to healthy 
tendons, and also the further research plan can be introduced. 
The pathology underlying patellar tendinosis was not clearly defined as recently 
as 1994，probably reflecting confusion arising from differences in nomenclature (Yu et 
al., 1995). Macroscopically, patients with patellar tendinosis, the patellar tendon below 
the proximal part of patellar tendon appears a little bulgy. The patellar tendon contains 
soft, yellow-brown, and disorganised tissue evident even to the naked eye. Under light 
microscopy, patellar tendinosis tissues characteristically demonstrate (1) 
hypercellularity, which tenocytes were more plentiful than in the normal tendon, lose 
their fine spindle shape, and nuclei appear more rounded. (2) hypervascularity, which a 
hypervascular zone may be seen on the tendon surface and there is abnormal small 
vessel growth into the tendon. (3) disorganization and loosening of collagen fibrils, 
where there is a decreased stainability of collagen fibrils with H & E staining, and 
collagen fibrils lose their parallel and well bondage structure appearing amorphous and 
disorganised collagen fibrils under polarized microscopy. (4) proteoglycans are 
markedly increased in the extra-cellular matrix. (5) lack of inflammatory cells 
infiltration, which is one of the most important characteristic of tendinosis, as this is 
what tendinosis is distinguished from tendinitis (Khan et al., 1999). 
Very similar histopathological changes occur in patients with Tendon Achilles 
tendinopathy, rotator cuff tendinosis as well as extensor carpi radialis brevis tendon 
tendinosis (tennis elbow)(Rolf et al.l997). 
. 17 
1.6 Study Plan 
In order to provide more information on the pathogenesis of patellar tendinosis, 
the further systematic characterization on human tendinosis tissues is needed, especially 
on the cellular level. In this study, the hypercellularity and the disorganization and 
loosening of collagen fibrils as well as the possible causes for pain and swelling were 
further characterized on human specimens of patellar tendinosis to compare with that of 
healthy patellar tendons. Since growth factors play a very important role in regulating 
the development and maturation of normal tendons as well as the repair of injured 
tendons, the histopathological alterations in patellar tendinosis tissues may result from 
the change of growth factors and receptors expression. In this study, the expression of 
growth factors has also been studied for their roles involved in pathogenesis of patellar 
tendinosis. 
1.6.1 Characterization on Hypercellularity 
Hypercellularity, being one of mentioned criteria for tendinosis and putatively 
resulted abnormal cellular activities, has not been demonstrated by objective measures. 
Neither has the activity of the "tendinosis cells" been demonstrated and the role of 
hypercellularity in pathogenesis of tendinosis never the less remains unexplored. 
The current study aimed to objectively verify the presence of hypercellularity 
and assess cell proliferation by analyzing the expression of proliferation cell nuclear 
antigen (PCNA), a protein only appearing in proliferating cell (Miyachi et al” 1978; 
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Matthews et al, 1984; Travali et al., 1989; Hall et al., 1990; Yu et al., 1992) in human 
patellar tendinosis tissues in comparison with healthy controls. 
1.6.2 Characterization on Disorganization and Loosening of Collagen 
In order to enunciate the cause of disorganization and loosening of collagen 
fibrils which is one of the characteristic histopathological alteration found in tendinosis, 
further characterizations on patellar tendinosis tissues is necessary. Since homeostasis of 
the extra-cellular matrix in tendon depends on major the balance between collagen 
synthesis and degradation, it is possible that there is a disturbance in both collagen 
synthesis and degradation. 
As mentioned previously, procollagen type I，which is the precursor of collagen 
type I，is synthesized by tenocytes. And during its synthesis there is an associated 
expression of hsp47 whose function is to assist correct folding and assembling of 
procollagen when there is an increased need of collagen synthesis or in response to 
injury and many other stresses. In patellar tendinosis, whether the statue of collagen 
synthesis alters, or whether there are present stress factors facilitating the alteration still 
remains unknown. On the other hand, collagen degradation is mainly conferred by 
MMPs，it is possible that the disturbance in collagen fibres in tendinosis is related to 
altered level and activities of MMPs and TIMPs. 
In the current study, the expression level of hsp 47，procollagen type I，MMPl 
and TIMPl in tendinosis and healthy patellar tendons were measured by 
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immunohistochemistry. By investigating both collagen synthesis and degradation 
potentials in tendinosis tissues, a better understanding on the origin of collagen matrix 
disturbance may be gained. 
1.6.3 Characterization on Inflammatory Response 
Chronic patellar tendinitis has been a common diagnosis for patellar tendinosis, 
but objective evidence of inflammatory changes has not been documented. Whether 
inflammatory cells have been infiltrated is not known, since the patellar tendinosis 
biopsies under examination come from patients with more than 6 months history of 
anterior knee pain. During the tendon healing processes, the first process is 
inflammatory phase. In this phase, a release of inflammatory mediators result in pain, 
swelling and erythema of tendon. Although in patellar tendinosis tissues, inflammatory 
cells are not found in an apparently "inflammed" soft tissues with regard to 
hypervascularization, edema, whereas tendon fibroblasts are actively proliferating as in 
early phase of tendon healing (Isabel et al., 1985), but an early inflammatory responses 
in the development of patellar tendinosis could not be ruled out. We are thus interested 
in detecting the presence of traces for inflammation in tendinosis tissues. 
Cyclo-oxygenase 2 (COX-2) is the rate-limiting enzyme for the synthesis of pro-
inflammatory prostaglandins (Zhang et aL, 1997). In contrast to COX-1 which is 
constitutively expressed, COX-2 is an inducible enzyme in virtually all tissues except 
kidney and brain (Vane et al., 1998). It is up-regulated upon the stimulation of pro-
inflammatory cytokines such as ILl and TNF, and leads to increased output of 
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prostaglandins such as PGE2, PGD2 that mediate local inflammatory and hyperalgesia 
response (Henke et al, 1987; Pilbeam et al., 1997). The detection of COX-2 expression 
in tendinosis tissues will thus provide information on the possible causes for pain and 
swelling and the traces of localized inflammatory response. 
1.6.4 Characterization on Growth Factors in Tendinosis 
The roles of growth factors in tendon healing have been broadly revealed by 
studying their expression profile. However, their expression profile in patellar tendinosis 
has not been studied yet. In this study, two most common growth factors of interesting in 
tendon which are T G P P and PDGFBB were detected their expression level in both 
patellar tendinosis and normal patellar tendon by immnohistochemistry. Also one of the 
growth factors receptor, PDGFRp, was detected its expression level to evaluate whether 
there is a change in the receptor level. 
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1.7 Objectives: 
The objectives of this study are listed as follows: 
1，To assess cellularity with respect to cell proliferation by detecting PCNA expression 
in patellar tendinosis compared to healthy controls. 
2，To assess collagen synthesis by detecting hsp47 and procollagen type I expression in 
patellar tendinosis compared to healthy controls. 
3，To assess collagen degradation by detecting MMPland TIMPl expression in patellar 
tendinosis compared to healthy controls. 
4，To assess collagen degradation by detecting in situ collagenases activities in patellar 
tendinosis compared to healthy controls. 
5，To characterize the inflammatory response by detecting one of inflammatory 
mediators COX-2 expression in patellar tendinosis compared to healthy controls. 
6，To characterize the growth factor expression profile by detecting TGppi and 
PDGFBB and P D G F R P expression in patellar tendinosis compared to healthy controls. 
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Figure 1.1 Anatomy of Patellar Tendon 
The figure showing anteroposterior (left) and lateral view (right) of 
patellar tendon. Patellar tendon, the extension of the common tendon of 
insertion of the quadriceps femoris muscle, takes its origin from the distal 
pole of the patella and inserts distally into the tibial tuberosity. 
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Figure 1.2 Ultrasonographic Appearance of Patellar 
Tendinosis 
Representative US images showing the characteristic sonographic 
hypoechogenic region around the proximal part of patellar tendon in 
patellar tendinosis (left). Usltrasonographic appearance of healthy 
patellar tendon is homeostatic echogenicity (right). 
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Figure 1.4 Histopathology of patellar tendinosis 
Representative H&E staining of healthy and tendinosis patellar 
tendon. A - Healthy patellar tendon; B 一 Tendinosis patellar tendon 
with (1) increased cell number and with less elongated cells, (2) 
disorganization and decreased stainability with Eosin of the extra-
cellular matrix, (3) no inflammatory cells infiltration; C -






2.1 HUMAN TISSUES 
The Human Research Ethics Committee of the Chinese University of Hong 
Kong has approved all sampling procedures. All human tissues were recruited from 
the Department of Orthopaedics and Traumatology, the Prince of Wales Hospital, 
Hong Kong. Both tendinosis and control subjects, being thoroughly informed on the 
procedures, completed consent forms prior to operation. 
2.1.1 Patellar Tendinosis Tissues 
2.1.1.1 Diagnosis of patellar tendinosis 
Patellar tendinosis was diagnosed with activity related longstanding 
localized pain in the patellar tendon, with tenderness on palpation around the 
proximal part of patellar tendon; with more than six months of insufficient non-
operative management including physiotherapeutic modalities and NSAIDs; and 
with a hypoechogenous area or a hyper intense area where correlate to the side of 
tenderness verified by ultrasound or MRI, respectively. 
2.1.1.2 Recruitment of patients 
Eleven patients were included in the current study. All of these patients 
fulfilled the clinical and radiological criteria for tendinosis but were otherwise 
healthy. Guided by the clinical findings and the images of ultrasound or MRI, the 
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tendinosis patellar tendon was exposed during operation. The pathological tissue 
was then removed under open visualization and a piece of tissue with a dimension of 
0.5x1.5cm preserved for subsequent analysis (Fig. 2.1). 
2.1.2 Healthy Patellar Tendon Tissues 
Twelve control subjects represented anterior cruciate ligament (ACL) 
deficient patients who were operated using the healthy patellar tendon as an autograft. 
During ACL reconstruction in the control subjects, a piece of healthy patellar tendon 
at a dimension of 0.2x0.5cm was removed from the remnant of the patellar tendon 
autograft. 
2.2 TISSUES COLLECTION AND PREPARATION 
All specimens were cleansed in sterile saline, part of the fresh tissue were 
reserved for frozen tissue sections, for detecting the activities of matrix proteinases 
by in situ zymography, while the rest fixed in 10% buffered formalin and then used 
to prepare 5 [im thick paraffin embedded sections, for histologic and 
immunohistochemical studies. 
2.3 HISTOLOGICAL STUDY ON HUMAN SPECIMENS 
For confirmation of histopathological characteristics on human patellar 
tendinosis tissues and comparison to that of healthy patellar tendon tissues, the 
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haematoxyline and eosin staining, polarization microscopy and Safranin O staining 
was applied. 
2.3.1 Haematoxyline and Eosin Staining 
The routine H&E staining was applied to reveal the microscopic appearance 
of all tendinosis and healthy patellar tendon specimens. As H&E staining is the 
commonest histological method studying the morphology of tissues. It can accurately 
reflect the alterations of cellularities and extra-cellular matrix of tissues to be 
examined. In brief, a 5 jim thick paraffin embedded section from each specimens was 
selected randomly, after rehydration, tissue sections were stained with haematoxyline 
for 10 minutes and then differentiated in acid alcohol to further develop colour. Eosin 
was then stained for another 10 minutes prior to serial dehydration and mounting. 
2.3.2 Safranine O Staining for Detection of Proteoglycans 
Increased proteoglycans content in the extra-cellular matrix is one of 
characteristics of tendinosis. For detection the PGs in the human tissues to be 
studied, Safrinin O staining was used. Safranin O staining is one of the histochemical 
staining methods to detect the proteoglycans since Safranin O can bind to both 
carboxyl and sulfate groups of PGs. 
2.3.2.1 Reagents and solution preparation 
0.1% Safranin O Solution 
Dissolved O.lg Safranin O (Sigma, Cat#p2067) in 100ml distilled 
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water. 
1% Acetic Acid 
Added 1ml 100% Acetic Acid into 99ml distill water. 
0.1% Fast Green 
Dissolved O.lg Fast Green FCF/C.I. 42053 in 100ml distilled water. 
2.3.2.2 Experimental procedure 
In brief, a 5 |im thick paraffin embedded section from each specimens was 
selected randomly, after rehydration, tissue sections were stained with 0.1% Fast 
Green for 1 minutes and then differentiated in 1% acid alcohol. 0.1% Safranin O was 
then stained for another 6 minutes prior to serial dehydration and mounting. 
2.3.3 Polarization Microscopy 
Another histopathological change of tendinosis is the disorganization of the 
extra-cellular matrix, which may due to the disturbance of collagen fibrils. 
Polarization microscopic examination is one of the best ways to reveal the structural 
changes of collagen fibrils. In this study, all tissues sections stained with Sanfranin O 
were also examined under polarization microscopy (Leica Cambridge Ltd) to reveal 
the morphology of collagen fibrils. 
2.4 IMMUNOHISTOCHEMICAL STAINING 
Immnohistochemistry was used because it is a simple, specific and sensitive 
method to identify cellular or tissue constituents (antigens) by means of antigen-
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antibody interactions. Immunohistochemistry can localize the target antigens in the 
tissues and the down-stream image analysis can also semi-quantify the expression of 
the target proteins. In this study, the expression of PCNA, HSP47, procollagen type I， 
MMPl, TIMPl, TGF(3, PDGFBB, PDGFRp was detected by immunohistochemical 
ABC method. 
2.4.1 Reagents and Solution Preparation 
Phosphate Buffered Saline (PBS) 
Dissolved 1.44g NaHP04 (Sigma, Cat#S0876), 0.24g KH2P04 (Sigma, 
Cat#P5379), 8.0g NaCl (Merck, Cat#106404), and 0.2g KCl (Merck, Cat#104936) in 
900ml distilled water. Adjusted pH to 7.4 and made the final volume of 1000ml with 
distilled water ‘ 
Citrate Buffer 
Solution A: 
Dissolved 2.10g citric acid (free acid, llfcOXMerck，Cat#l 12014) in 100ml 
distilled water. 
Solution B: 
Dissolved 14.705g citric acid (Trisodium dihydrate) (Merck, cat#l 12005) in 
500ml distilled water. 
Solution C: 
Mixed one part of solution A (100ml) and four parts of solution B (400ml). 
Final 0.01 M citrate buffer, pH 6.0 
Diluted 50ml of solution C with 450ml distilled water and adjusted the pH 




Diluted the 0.25% trypsin solution (Gibco, Cat#25200-056) with PBS to the 
final concentration of 0.05%. 
l%Bovine Serum Albumin- Phosphate Buffered Saline (1%BSA-PBS) 
Dissolved l.Og of bovine serum albumin (Sigma, Cat#A7888) in 100ml 
PBS. Stirred to ensure the albumin dissolved completely. 1%BSA-PBS was used as a 
blocking serum and the entire primary and secondary antibody were diluted by 
1%BSA-PBS at different dilution factor specified below. 
Primary Antibody to: (Diluted: PBS-BSA) 
A mouse monoclonal anti-human PCNA antibody (Oncogens research 
product, Cambridge, MA, Cat#IM24L) at a dilution of 1:100 
A mouse monoclonal anti-human hsp47 antibody (StressGen, Victoria, BC 
Canada, Cat#AB-0341c) at a dilution of 1:1000. 
A mouse monoclonal anti-human procollagen type I antibody (Chemicon, 
Temecula, CA, Cat# MAB-1913) at a dilution of 1:500. 
A mouse monoclonal anti-human MMPl antibody (Oncogene research 
products, Cambridge, MA, Cat#IM35L) at a dilution of 1:50. 
A mouse monoclonal anti-human TIMPl antibody (Oncogene research 
products, Cambridge, MA, Cat#IM32L) at a dilution of 1:50. 
A mouse monoclonal anti-human COX-2 antibody (Oncogene research 
products, Cambridge, MA, Cat#SC-1745) at a dilution of 1:200. 
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A chicken monoclonal anti-human TGppi antibody (R&D Systems, 
Cat#AB-101-NA) at a dilution of 1:400. 
A goat monoclonal anti-human PDGFBB antibody (R&D SYSTEMS, 
Cat#AB-220-NA), at a dilution of 1:200 
A goat monoclonal anti-human PDGFRP antibody (Santa Cruz, Cat#SC-
127), at a dilution of 1:100. 
Biotinvlated Secondary Antibody to: (Diluted: PBS-BSA) 
A biotinylated rabbit anti-mouse IgG (DAKO，Glostrup, Denmark, 
Cat#E0354) 
A biotinylated rabbit anti-goat IgG (DAKO, Glostrup, Denmark, Cat#E0466) 
A biotinylated rabbit anti-chicken IgG (Chemicon, Cat#AP161B). 
ABC Complexes/HRP 
Avidin-biotin methods was used to detect the biotinylated secondary 
antibodies by using ABC Complexes/HRP Kit (DAKO, Cat#K0376). 
Diaminobenzidein (DAB) Solution 
Diaminobenzidein(DAB) (DAKO,Cat#K3465) was used as the substrate for ‘ 
peroxidase to develop color. 
2.4.2 Experimental Procedure 
Tissue sections were mounted on 3-aminopropyl-triethoxy-silane (SIGMA 
Chemical) and dried overnight at 40°C. After removal of paraffin and dehydration in 
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graded alcohol, consecutive paraffin sections were used for immunohistochemical 
staining of the proteins and were quenched with 0.5% hydrogen peroxide for 20 
minute; then they were placed in a lO-mmol/L citrate buffer solution (pH 6) and 
boiled in a microwave oven with high power (700 W) for 1 minute. After a brief 
digestion with 0.05% trypsin for 20 minutes, the consecutive sections were incubated 
with primary antibody before incubated with 1% bovine serum albumin in 
phosphate-buffered saline (PBS) for 20 minutes. Supplementation of primary 
antibodies depends on which target antigen to be detected. A mouse monoclonal anti-
human PCNA antibody (Oncogens research product, Cambridge, MA, Cat#IM24L) 
at a dilution of 1:100; A mouse monoclonal anti-human hsp47 antibody (StressGen, 
Victoria, BC Canada, Cat#AB-0341c) at a dilution of 1:1000; A mouse monoclonal 
anti-human procollagen type I antibody (Chemicon, Temecula, CA, Cat# MAB-1913) 
at a dilution of 1:500; A mouse monoclonal anti-human MMPl antibody (Oncogene 
research products, Cambridge, MA, Cat#IM35L) at a dilution of 1:50; A mouse 
monoclonal anti-human TIMPl antibody (Oncogene research products, Cambridge, 
m a , Cat#IM32L) at a dilution of 1:50; A mouse monoclonal anti-human COX-2 
antibody (Oncogene research products, Cambridge, MA, Cat#SC-1745) at a dilution 
of 1:200; A chichen monoclonal anti-human TGppi antibody (R&D Systems, 
Cat#AB-101-NA) at a dilution of 1:400; A goat monoclonal anti-human PDGFBB 
antibody (R&D SYSTEMS, Cat#AB-220-NA), at a dilution of 1:200. A goat 
monoclonal anti-human PDGHRp antibody (Santa Cruz, Cat#SC-127), at a dilution 
of 1:100，were applied on the tissues sections respectively and incubated in a humid 
chamber at 4° overnight. Primary antibodies were diluted in PBS-BSA. Negative 
stain controls were prepared by omitting the primary antibody. 
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After thorough washing with PBS, the sections were incubated with 
secondary antibodies. The choice of secondary antibodies depended on the species 
from which the primary antibody was raised. For example, the primary antibody is a 
mouse anti-human antibody, a secondary antibody of biotinylated anti-mouse IgG 
(DAKO, Glostrup, Denmark) was used. The sections were incubated in avidin-biotin 
complex (DAKO) for 60 minutes. Finally, 1% solution of diaminobenzidine 
tetrahydrochloride (DAB) was used to develop colour in the presence of H2O2. 
* 
Haematoxyline was used as a counter stain to reveal the nuclei. 
2.5 IMAGE ANALYSIS 
Statistical estimates of immunohistochemical staining results by using 
computer assisting image analysis system are not only easier to -apply but can give 
any required degree of accuracy subjectively. The processes include image 
acquisition, which is video digitization, image processing and image analysis, which 
is to use specific software to perform the measurement. 
2.5.1 Equipment 
Immunostaining results were analyzed with LEICA Q500MC Computed 
Assistant Image Analysis System (Leica Cambridge Ltd.). 
2.5.2 Procedures 
Firstly, all slides were investigated in a meandering way, to examine the 
. 35 
quality of brown immunopositive staining of all antigens to be examined, and the 
pixel threshold values can be defined in accordance with visual inspection. To 
minimize assessment bias a double-blind design was used. Measurements were 
performed using a 40 X objective, ten viewing fields (0.038 mm each) per slide 
were sampled systematically to avoid allocation bias. Viewing fields including 
endothelial cells and synovium cells were skipped and replaced by adjacent viewing 
fields. 
For immunohistometric measurement, first the Hue-Saturation-Intensity 
colour coding was used to detect the colour and measurement of mean colour 
saturation of immunopositive stains. The pixel threshold values (Full range 0-255) of 
brown color, representing the immunopositive cells, was defined respectively 
depending on different target antigens to be detected as listed below: 
PCNA: Hue: 128-142; Saturation: 0-255; Intensity: 22-128. 
Hsp47: Hue: 128-142; Saturation: 0-255; Intensity: 22-128. 
Procollagen type I: Hue: 128-142; Saturation: 0-255; Intensity: 22-128. 
MMPl: Hue: 128-142; Saturation: 0-255; Intensity: 22-128. 
TIMPl: Hue: 128-142; Saturation: 0-255; Intensity: 22-128. 
COX-2: Hue: 138-158; Saturation: 0-255; Intensity: 60-172 
TGFPI: Hue: 138-158; Saturation: 0-255; Intensity: 60-172 
PDGFBB： Hue: 138-158; Saturation: 0-255; Intensity: 60-172 
PDGFRp: Hue: 138-158; Saturation: 0-255; Intensity: 60-172 
Similarly, the pixel threshold values for brown and blue color, representing the total 
number of cell, was determined with: 
PCNA: Hue: 30-142; Saturation: 0-255; Intensity: 22-145. 
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Hsp47: Hue: 30-142; Saturation: 0-255; Intensity: 22-145. 
Procollagen type I: Hue: 30-142; Saturation: 0-255; Intensity: 22-145. 
MMPl: Hue: 30-142; Saturation: 0-255; Intensity: 22-145. 
TIMPl: Hue: 30-142; Saturation: 0-255; Intensity: 22-145. 
COX-2: Hue: 20-158; Saturation: 0-255; Intensity: 60-172 
TGF(3l: Hue: 20-158; Saturation: 0-255; Intensity: 60-172 
PDGFBB: Hue: 20-158; Saturation: 0-255; Intensity: 60-172 
PDGFRP: Hue: 20-158; Saturation: 0-255; Intensity: 60-172 
The percentages of the immunopositive cells were obtained by counting brown cells 
and total cell number (brown + Blue). A proliferative index defined as the percentage 
of the PCNA immunopositive nuclei with to the total cell nuclei. The 
immunopositivities, which represents the cellular expression level of the target 
antigen, were defined as mean optical density (OD) of brown colour of all selected 
features (immunopositive cells) in the viewing field. According to the manual of 
LEICA Q500MC Image Analysis System, optical density of colour = log {255/255-
satuation of colour}. 
2.6 IN SITU ZYMOGRAPHY 
For further comparison of the proteolytic activity between tendinosis and normal 




Mixed 2mg fluorescein isothiocyanate(Sigma, Cat#F5796) with 40mg total 
gelatin(Sigma, Cat#G5384) and dissolved into 5ml 0.25M carbonate buffer(pH 9.0) 
at room temperature for 24h. Separate the conjugated FITC-gelatin from the free 
fluorochrome by passing the mixture down a Sephadex G-15 column equilibrated 
with distilled water. Collection and lyophilization of FITC-gelatin. 
FITC-gelatin glass slide 
1% agarose (Sigma, Cat#A9918) melted in 50 mmol/L Tris-HCl, pH 7.4, containing 
50mM sodium chloride, 10 mmol/L calcium chloride and 0.05% Brij 35 was mixed 
1:1 with 1 mg/mL gelatin-FITC and applied as a film to glass slides. 
Incubation buffer 
50 mmol/L Tris-HCl, pH 7.4, containing 50mM sodium chloride, 10 mmol/L 
calcium chloride and 0.05% Brij 35 (Sigma, Cat#P1254) 
EDTA solution 
10 mM disodium ethylenediaminetetraacetate (Sigma, Cat#E8008). 
2.6.2 Procedures 
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Patellar tendinosis tissues and healthy controls were prepared as 5 |Lim thick 
frozen sections and embedded without fixation in Tissue-Tek OCT compound (Miles, 
Inc., Elkhart, Indiana). In situ gelatin zymography was performed according to (4). 
Briefly, sections were applied onto FITC- gelatin coated glass slides, incubated with 
incubate buffer in a humid chamber at 37°C. Under epifluorescent examination, 
gelatinolytic activity was detected as dark-appearing zones lacking fluorescence as a 
result of digestion of the substrate-fluorescent molecule complexes. Gelatin digestion 
indicated gelatinase activity in excess of TIMPs. For control, slides with or without 
proteinase inhibit buffer EDTA (20 mmol/L) were prepared. 
Specimens were examined at time point Oh, 2h and 24h. Digestion in normal 
and tendinosis patellar tendon specimens was described qualitatively and compared 
at consistent time intervals of incubation. 
2.7 STATISTIC ANALYSIS 
SPSS 9.0 was used for all statistical tests. After checking for normal 
distribution by Kolmogorov-Smimov test, independent sample t-test was used to 
detect significant differences of semi-quantitative immunohistometry between 
tendinosis and healthy patellar tendon with respect to percentage immunopositive 
cells and mean optical density of all target antigens. Fisher's Exact Test was used to 
assess the association of patellar tendinosis with the proteolytic activities by in situ 
zymography. Potential confounding factors such as age and gender of the subjects 
were controlled using stepwise logistic regression. The significance level was set at 
0.05. 
. 39 
Figure 2.1 Sampling of patellar tendinosis tissue 
Figures showing surgery for the tendinosis patient was performed and 
guided by the clinical findings including the images of ultrasound 





Figure 2.2 LEICA Q500MC Image Analysis System 
Immunostaining results were analyzed with LEICA Q500MC 
Computed Assistant Image Analysis System (Leica Cambridge Ltd.). 
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3 RESULTS 
3.1 HUMAN SAMPLES 
3.1.1 Patellar Tendinosis Patients: 
The information of all human samples used in current study is listed in table 
3.1. 
Total eleven patellar tendinosis patients were included in current study. 
There are nine male and two female, the age distribution of patient range from 15 to 
40 years old, average 31 years old. The side involved is seven right knees and four 
left knees. All of these patients fulfilled the clinical and radiological criteria for 
tendinosis, which they all have activity related longstanding localized pain in the 
proximal part of patellar tendon, and with tenderness on palpation with a low 
echogenous area or a hyper intense area verified by ultrasound or MRI, respectively. 
They all participated in various recreational sports. Two of eleven patients had high 
level of activities, which one is professional badminton player and another is runner. 
Seven of eleven patients had recreational or moderate level of activities, which these 
patients played some kinds of sport times a week. Two of eleven patients had no 
vigorous physical activities, which they seldom play sport. All patients had 
undergone physiotherapy (range 3-8 months), and all had used oral NSAID treatment 
over shorter periods of time. In no case they had received local cortisone injections. 
At time of surgery, all patients failed to response to conservative modalities, 
presenting persistent pain and affecting activities of daily life, indicated for surgical 
treatment. 
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3.1.2 Healthy Control Group: 
Total twelve control subjects were included in current study. There are eight 
male and four female, the age distribution of patient range from 16 to 38 years old, 
average 31 years old. There are six right and six left knees. The control subjects had 
no previous history or clinical signs of patellar tendon injury. All of these patients 
had used occasional NSAID and physiotherapy during a pre-operative planning 
session for at least 6 months from the injury. They all participated in recreational 
sports. 
3.2 HISTOLOGICAL STUDY ON HUMAN SPECIMENS 
3.1.1 Gross Morphology 
Patients with patellar tendinosis, the tendon sheath of patellar tendon 
appears little thicken, but there is no redness, hyperemia, or inflammatory exudation. 
The whole patellar tendon lost glistening, stringy, and white appearance reflecting 
dark yellow colour. The patellar tendon below the inferior pole of patella appears 
little bulgy and there is a hypervascular zone on tendon surface. The patellar 
tendinosis tissues contain soft, yellow-brown, and disorganized tissue evident even to 
the naked eye. (Fig.3.1) 
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The tendon sheath of patellar tendon from healthy control is not thickening. All 
healthy control patellar tendons appear glistening, stringy, and white and there is not 
a hypervascular zone on tendon surface. 
3.2.2 Haematoxyline and Eosin Staining 
H & E staining showed that all patellar tendinosis samples the number of 
cells was significantly increased, and tenocytes appeared less elongated together with 
a loss of alignment. There was a decreased stainability of eosin and disorganization 
in the extra-cellular matrix in all tendinosis tissues. The area with increased cell 
number is concomitant that of disorganized extra-cellular matrix in all patellar 
tendinosis. There was an increased vessel ingrowth in tendinosis. No inflammatory 
cells can be identified in both tendinosis and healthy control tendons. Whereas no 
histological abnormalities were found in the healthy patellar tendon controls. 
(Fig.3.2) 
3.2.3 Safranin O Staining for Detection of Proteoglycans 
Safranin O staining on tendinosis and normal patellar tendon showed there 
was, to various extents, a positive staining in extra-cellular matrix in all tendinosis 
samples in contrast to no staining in healthy controls. Indicating there is an increased 
proteoglycans content in patellar tendinosis. The region of positive staining is 
consistent with that of hypercellularty and disorganized extra-cellular matrix. 
(Fig.3.3) 
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3.2.4 Polarization Microscopy 
Under examination of polarization microscopy, The characteristic reflective 
polarized light appearance of normal collagen is lost in patellar tendinosis samples. 
Tendinosis patellar tendons showed loss of crimp structure of collagen matrix in 
contrast to the healthy control tendons. The characteristic feature of disorganization 
of collagen fibrils was demonstrated on all patellar tendinosis samples. (Fig. 3.4) 
In general, histologic characterization on human tissues at present study 
showed that all patellar tendinosis samples, to various extents, exhibited 
hypercellularity, disrupted collagen matrix, increased proteoglycans content and no 
inflammatory cells infiltration as revealed by H & E staining, Sanfranine O staining as 
well as polarization microscopy. No histological abnormalities were found in the 
healthy patellar tendon controls. The results showed that the human samples from 
patellar tendinosis group are consistent in histopathological findings and eligible for 
further characterization by comparison with healthy controls.. 
3.3 IMAGE ANALYSIS 
3.3.1 Immunohistochemistry of PCNA 
The mean total cell number per viewing field is 56,52±6.2* in patellar 
tendinosis group while in healthy controls the mean total cell number per viewing 
field is 9.26±1.2*. The objective measurement of hypercellularity by the 
immunohistochemical stain for PCNA in tendinosis and controls showed that the 
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increase in cell number in tendinosis tissues was statistically significant (pcO.OOl). 
On the other hand, P C N A staining showed that the proliferation index (PI), which 
defined as the percentage of P C N A immunopositive cells per viewing field, is 
35.45±3.0* in patellar tendinosis group compared to 7.68±1.2* in healthy controls. 
Our results demonstrated a higher proliferative index (pcO.OOl) in tendinosis tissues, 
indicating that the hypercellularity is likely to be caused by an increased 
proliferation. (Data are presented as mean 士SD.* marks statistical significance for 
independent t test at p< 0.01). 
The results of immunohistometric measurements of P C N A are shown in 
Figure 3.5 and 3.6. The immunohistochemical stain for P C N A in tendinosis and 
controls is shown in Figure 3.7. 
3.3.2 Immunohistochemistry of hsp47 
The optical density of hsp47, which presenting the cellular expression level 
of hsp47, is 0.09605士0.02658 in patellar tendinosis group compared to 
0.03919土0.03161 in healthy control group. The percentage of immunopositive cells 
for hsp47 in patellar tendinosis group is 46.12土4.63 contrast to 14.86土3.14 in healthy 
control group. Our results showed that both the optical density of hsp47 and the 
percentage of immunopositive cells for hsp47 were higher in tendinosis tissues as 
compared to healthy control (p<0.001*). (Data are presented as mean ±SD.* marks 
statistical significance for independent t test at p< 0.01). 
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The results of immunohistochemistry comparing the optical density of 
hsp47 and percentage of hsp47 immunopositive cells were shown in Figure 3.8 and 
3.9. The immunohistochemical staining for hsp47 was shown in Figure 3.10. 
3.3.3 Immunohistochemistry of procollagen type I 
The optical density of procollagen type I，which presenting the cellular 
expression level of procollagen type I, is 0.1208±0.04226 in patellar tendinosis group 
as compared to 0.08915土0.04576 in healthy control group. The statistic result on the 
optical density of procollagen type I in tendinosis and healthy control showed no 
significant difference (p=0.101). The percentage of immunopositive cells for 
procollagen type I in patellar tendinosis group is 39.36±4.69* contrast to 
19.32±2.34*in healthy control group. The results showed that the percentage of cells 
expressing procollagen type 1 was higher in tendinosis tissues (p=0.001). (Data are 
presented as mean ±SD. Statistical significance for independent t test was set at p< 
0.01). 
The results of immunohistochemistry comparing the optical density of 
procollagen type I and percentages of procollagen type I immunopositive cells were 
shown in Figure 3.11 and 3.12. The immunohistochemical staining for procollagen 
type I was shown in Figure 3.13. 
3.3.4 Immunohistochemistry of MMPl 
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The optical density of MMPl, which presenting the cellular expression level 
of M M P l , is 0.1441±0.02378 in patellar tendinosis group contrasted to 
0.07481土0.03982 in healthy control group. The percentage of immunopositive cells 
for M M P l in patellar tendinosis group is 47.00±2.40 contrast to 17.70±2.59 in 
healthy control group. Our results showed that both the optical density of M M P l and 
the percentage of immunopositive cells for M M P l were higher in tendinosis tissues 
as compared to healthy control (pcO.OOl*). (Data are presented as mean 士SD.* 
marks statistical significance for independent t test at p< 0.01). 
The results of immunohistochemistry comparing the optical density of 
M M P l and percentages of M M P l immunopositive cells were shown in Figure 3.14 
and 3.15. The immunohistochemical staining for M M P l was shown in Figure 3.16. 
3.3.5 Immunohistochemistry of TIMPl 
r 
The optical density of TIMPl, which presenting the cellular expression level 
of TIMPl, is 0.01760士0.01288 in patellar tendinosis group contrasted to 
0.03819土0.01914 in healthy control group. The percentage of immunopositive cells 
for TIMPl in patellar tendinosis group is 3.36±0.92* contrast to 23.48±4.30*in 
healthy control group. Our results showed that both the optical density of TIMPl and 
the percentage of immunopositive cells for TIMPl were lower in tendinosis tissues 
as compared to healthy control (pcO.OOl*). (Data are presented as mean 土SD.* 
marks statistical significance for independent t test at p< 0.01). 
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The results of immunohistochemistry comparing the optical density of 
TIMPl and percentages of TIMPl immunopositive cells were shown in Figure 3.17 
and 3.18. The immunohistochemical staining for TIMPl was shown in Figure 3.19. 
3.3.6 Immunohistochemistry of COX-2 
The optical density of COX-2, which presenting the cellular expression 
level of COX-2, is 0.1473±0.02254 in patellar tendinosis group contrasted to 
0.05464土0.03243 in healthy control group. The percentage of immunopositive cells 
for COX-2 in patellar tendinosis group is 33.09士4.07 contrast to 2.55±0.69 in healthy 
control group. Our results showed that both the optical density of COX-2 and the 
percentage of immunopositive cells for COX-2 were higher in tendinosis tissues as 
compared to healthy control (pcO.OOl*). (Data are presented as mean 土SD.* marks 、 
statistical significance for independent t test at p< 0.01). 
The results of immunohistochemistry comparing the optical density of COX-2 and 
percentages of COX-2 immunopositive cells were shown in Figure 3.20 and 3.21. 
The immunohistochemical staining for COX-2 was shown in Figure 3.22. 
3.3.7 Immunohistochemistry ofTGFpi 
The optical density of TGppi, which presenting the cellular expression 
level of TGppi, is 0.1106±0.01860 in patellar tendinosis group contrasted to 
0.05263士0.02667 in healthy control group. The percentage of immunopositive cells 
for TGF(3l, in patellar tendinosis group is 56.40土 16.97 contrast to 23.06士 13.22 in 
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healthy control group. Our results showed that both the optical density of TGppi and 
the percentage of immunopositive cells for TGF(3l were higher in tendinosis tissues 
as compared to healthy control (p<0.001*). (Data are presented as mean 土SD.* 
marks statistical significance for independent t test at p< 0.01). 
The results of immunohistochemistry comparing the optical density of 
TGppi and percentages of TGppi immunopositive cells were shown in Figure 3.23 
and 3.24. The immunohistochemical staining for TGFpl was shown in Figure 3.25. 
3.3.8 Immunohistochemistry of PDGFBB 
The optical density of PDGFBB, which presenting the cellular expression 
level of PDGFBB, is 0.03928土0.01114 in patellar tendinosis group contrasted to 
0.03147士0.09270 in healthy control group. The percentage of immunopositive cells 
for PDGFBB, in patellar tendinosis group is 18.92±1.68* contrast to 15.35±1.25*in 
healthy control group. Our results showed that both the optical density of PDGFBB 
and the percentage of immunopositive cells for PDGFBB were no significant 
difference in tendinosis tissues as compared to healthy control (p=0.081 and 
p=0.099, respectively). (Data are presented as mean 土SD. Statistical significance for 
independent t test was set at p< 0.01). 
The results of immunohistochemistry comparing the optical density of 
PDGFBB and percentages of PDGFBB immunopositive cells were shown in Figure 
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3.26 and 3.27. The immunohistochemical staining for PDGFBB was shown in Figure 
3.28. 
3.3.9 Immunohistochemistry of PDGFRp 
The optical density of PDGFR(3, which presenting the cellular expression 
level of PDGFR, is 0.06973土0.01238 in patellar tendinosis group contrasted to 
0.02704±0.01485 in healthy control group. The percentage of immunopositive cells 
for PDGFRP is 66.88±3.0 in patellar tendinosis group contrast to 23.95±4.1 in 
healthy control group. Our results showed that both the optical density of PDGFRP 
and the percentage of immunopositive cells for PDGFR(3 were higher in tendinosis 
tissues as compared to healthy control (pcO.OOl*). (Data are presented as mean 
士SD.* marks statistical significance for independent t test at p< 0.01). 
The results of immunohistochemistry comparing optical density of PDGFRp 
and percentages of PDGFRP immunopositive cells were shown in Figure 3.29 and 
3.30. The immunohistochemical staining for PDGFRP was shown in Figure 3.31. 
3.3.10 Summary of Image Analysis of Immunohistochemical staining 
Summary of semi-quantitation of immunohistometry was showed in Table 
3.2. There was a higher proliferative index in patellar tendinosis compared to healthy 
patellar tendon. Both the optical density and percentage of immunopositive cells of 
hsp47，MMPl, COX-2, TGF|3l and PDGFRP were significant higher in patellar 
tendinosis than in healthy controls. Both the optical density and percentage of 
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immunopositive cells of TIMPl were significant lower in patellar tendinosis than in 
healthy controls. Both the optical density and percentage of immunopositive cells of 
PDGFBB were no significant difference between patellar tendinosis and healthy 
controls. The percentage of procollagen type I immunopositive cells was higher in 
patellar tendinosis, but the optical density of procollagen type I was no significant 
difference between patellar tendinosis and healthy controls. The influence of two 
potential confounding factors, age and gender, to the percentage of immunopositive 
cells and the optical density of target proteins in semi-quantitative 
immunohistometry was not statistically significant. 
3.4 IN SITU ZYMOGRAPHY 
At zero-hour time point of incubation, there was no any dark zones could be , 
y 
seen under fluorescence microscopy on both patellar tendinosis and healthy control 
tissues (Fig.3.32). At two-hour time point of incubation, the presence of dark zones : 
；i 
could be seen in each of patellar tendinosis group, contrasted to no dark zones seen ’ 
in all healthy controls (Fig.3.33). At twenty-four-hour time point of incubation, more 
dark zones could be seen in patellar tendinosis tissues, and still there was no dark 
zone present in healthy controls (Fig 3.34). Fisher's Exact Test demonstrated that the 
association between patellar tendinosis and increased proteolytic activities was 
statistically significant (pcO.OOl) (Table 3.3). 
In situ gelatin zymography demonstrated higher proteolytic activity in tendinosis 
than healthy tendon tissue as demonstrated by the presence of many dark zones, 
which indicated the lack of fluorescence due to digestion of the substrate fluorescent 
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complexes. The proteolytic activity mainly resided in the hypercellular areas with 
collagen lossing alignment in tendinosis tissue but absent in healthy controls 
(Fig.3.35). For controls, slides incubated with metalloproteases inhibitor (EDTA) 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.1 Gross Morphology of Patellar Tendinosis Tissues 
Figures showing the tendon sheath of tendinosis patellar tendon 
appears little thicken, but there is no redness, hyperemia, or 
inflammatory exudation. The whole patellar tendon lost glistening, 
stringy, and white appearance reflecting dark yellow colour (Left). 
Patellar tendinosis tissues contain soft, yellow-brown, and 
disorganized tissue evident even to the naked eye (Right). 
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Figure 3,2 Haematoxyline and Eosin staining of patellar 
tendinosis and healthy patellar tendon 
A: H & E staining showed the number of cell increased in tendinosis 
patellar tendon, and tenocytes appeared less elongated and loss of 
alignment. There was a decreased stainability of eosin and 
disorganization in the extra-cellular matrix in tendinosis patellar 
tendon tissue. B: H & E staining showed healthy patellar tendon 
consists of dense, parallel and slightly wavy collagen bundles. 
Between the collagen bundles there is a fairly even, sparse distribution 
of tenocytes with thin, wavy nuclei. No inflammatory cells could be 
identified in both the tendinosis and healthy patellar tendons. 
(Magnification: 400X) 
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Figure 3,3 Safranin O staining of patellar tendinosis and 
healthy patellar tendon 
Representative pictures showing positive Safranin O staining in extra-
cellular matrix in tendinosis patellar tendon (A) in contrast to no 
staining in healthy control (B). Indicating there is an increased 
proteoglycans content in patellar tendinosis. Magnification: 200X. 
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Figure 3.4 Polarization microscopy of patellar tendinosis and 
healthy patellar tendon 
Representative pictures showing under examination of polarization 
microscopy, tendinosis patellar tendon (A) showed loss of crimp 
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Figure 3.5 Total cell numbers per viewing field 
Blot plot showing total cell number per viewing field of patellar 
tendinosis and healthy patellar tendon. Patellar tendinosis showed higher 
total cell number when compare with healthy patellar tendon. 
Independent t-test showed a significant difference of the total cell number 
between patellar tendinosis and healthy patellar tendon (pcO.OOl) 
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Figure 3.6 Proliferative Index 
Blot plot showing proliferative index, which was defined as the 
percentage of PCNA immunopositive cells per viewing field, of patellar 
tendinosis and healthy patellar tendon. Patellar tendinosis fibroblasts 
showed higher proliferative index when compare with healthy patellar 
tendon. Independent t-test showed a significant difference of the 
proliferative index between patellar tendinosis and healthy patellar tendon 
(pcO.OOl) indicating a higher cell proliferation in patellar tendinosis. 
60 
, ?、‘，— I K / . i 、虞; ^ ^ 、：：. 
• ^ � � ^ � . ... 
• s - . . B 
： 窗 寶 : ? : . 暴 ? : 1 漏S::、義 
( , -
• •： ：- ：•:, 1 - ： _ 翁 场 導 編 職 蘇 _ 糖 ; ： ’ 卩 • . . i 
Figure 3.7 Immunohistochemical stain for PCNA 
A: The brown colour presented immunopositive stain with PCNA was 
localized in tenocytes of tendinosis patellar tendon section (arrow), 
indicating the tenocytes were proliferating cells. B: No 
immunopositive stain with PCNA was found in the healthy patellar 
tendon section. The negative control was done by omitting the primary 
abtibody for PCNA (C: patellar tendinosis; D: healthy patellar 
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Figure 3.8 Percentage of hsp47 immunopositive cells 
Blot plot showing percentage of hsp47 immunopositive cells per viewing 
field of patellar tendinosis and healthy patellar tendon. Patellar tendinosis 
showed higher percentage of hsp47 immunopositive cells when compare 
with healthy patellar tendon. Independent t-test showed a significant 
difference of the percentage of hsp47 immunopositive cells between 
patellar tendinosis and healthy patellar tendon (p <0.001). 
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Figure 3,9 Expression level of hsp47 
Blot plot showing optical density presenting expression level of hsp47 per 
viewing field in patellar tendinosis and healthy patellar tendon. Patellar 
tendinosis showed higher optical density of hsp47 when compare with 
healthy patellar tendon. Independent t-test showed a significant difference 
of the optical density of hsp47 between patellar tendinosis and healthy 
patellar tendon (p <0.001) indicating a higher cellular expression of hsp47 
in patellar tendinosis. 
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Figure3.10 Immunohistochemical stain for HSP47 
Representative pictures showing hsp47 expression in tendinosis patellar 
tendon (A) and (B) healthy patellar tendon. Immunohistochemical 
staining using monoclonal rabbit anti-human hsp47 antibody. 
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Figure 3.11 Percentage of procollagen typr I immunopositive 
cells 
Blot plot showing percentage of procollagen type I immunopositive cells 
per viewing field of patellar tendinosis and healthy patellar tendon. 
Patellar tendinosis showed higher percentage of procollagen type I 
immunopositive cells when compare with healthy patellar tendon. 
Independent t-test showed a significant difference of the percentage of 
procollagen type I immunopositive cells between patellar tendinosis and 
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Figure 3.12 Expression level of procollagen type I 
Blot plot showing optical density presenting expression level of 
procollagen type I per viewing field in patellar tendinosis and healthy 
patellar tendon. Independent t-test showed no significant difference of the 
optical density of procollagen type I between patellar tendinosis and 
healthy patellar tendon (p =0.101) indicating no difference of cellular 
expression of procollagen type I between patellar tendinosis and healthy 
controls. 
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Figure3_13 Immunohistochemical stain for Procollagen type I 
Representative pictures showing procollagen type I expression in 
tendinosis patellar tendon (A) and (B) healthy patellar tendon. The 
negative control was done by omitting the primary abtibody for 
procollagen type I (C: patellar tendinosis; D: healthy patellar tendon). 
Immunohistochemical staining using monoclonal mouse anti-human 
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Figure 3,14 Percentage of MMP1 immunopositive cells 
Blot plot showing percentage of M M P l immunopositive cells per 
viewing field of patellar tendinosis and healthy patellar tendon. Patellar 
tendinosis showed higher percentage of M M P l immunopositive cells 
when compare with healthy patellar tendon. Independent t-test showed a 
significant difference of the percentage of M M P l immunopositive cells 
between patellar tendinosis and healthy patellar tendon (p <0.001). 
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Figure 3.15 Expression level of MMP1 
Blot plot showing optical density presenting expression level of M M P l 
per viewing field in patellar tendinosis and healthy patellar tendon. 
Patellar tendinosis showed higher optical density of M M P l when 
compare with healthy patellar tendon. Independent t-test showed a 
significant difference of the optical density of M M P l between patellar 
tendinosis and healthy patellar tendon (p <0.001) indicating a higher 
cellular expression of M M P l in patellar tendinosis. 
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Figure3_16 Immunohistochemical stain for MMP1 
Representative pictures showing M M P l expression in tendinosis patellar 
tendon (A) and (B) healthy patellar tendon. The negative control was 
done by omitting the primary abtibody for M M P l (C: patellar tendinosis; 
D: healthy patellar tendon). Immunohistochemical staining using 
monoclonal mouse anti-human M M P l antibody. Haematoxyline was 
used as a counter stain. Magnification: 400X. 
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Figure 3,17 Percentage of TIMP1 immunopositive cells 
Blot plot showing percentage of TIMPl immunopositive cells per 
viewing field of patellar tendinosis and healthy patellar tendon. Patellar 
tendinosis showed lower percentage of TIMPl immunopositive cells 
when compare with healthy patellar tendon. Independent t-test showed a 
significant difference of the percentage of TIMPl immunopositive cells 
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Figure 3.18 Expression level of TIMP1 
Blot plot showing optical density presenting expression level of TIMPl 
per viewing field in patellar tendinosis and healthy patellar tendon. 
Patellar tendinosis showed lower optical density of TIMPl when compare 
with healthy patellar tendon. Independent t-test showed a significant 
difference of the optical density of TIMPl between patellar tendinosis 
and healthy patellar tendon (p <0.001) indicating a lower cellular 
expression of TIMPl in patellar tendinosis. 
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Figure3.19 Immunohistochemical stain for TIMPl 
Representative pictures showing TIMPl expression in tendinosis patellar 
tendon (A) and (B) healthy patellar tendon. The negative control was 
done by omitting the primary abtibody for TIMPl (C: patellar tendinosis; 
D: healthy patellar tendon). Immunohistochemical staining using 
monoclonal mouse anti-human TEMPI antibody. Haematoxyline was 
used as a counter stain. Magnification: 400X. 
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Figure 3. 20 Percentage of COX-2 immunopositive cells 
Blot plot showing percentage of COX-2 immunopositive cells per 
viewing field of patellar tendinosis and healthy patellar tendon. Patellar 
tendinosis showed higher percentage of COX-2 immunopositive cells 
when compare with healthy patellar tendon. Independent t-test showed a 
significant difference of the percentage of COX-2 immunopositive cells 
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Figure 3.21 Expression level of COX-2 
Blot plot showing optical density presenting expression level of COX-2 
per viewing field in patellar tendinosis and healthy patellar tendon. 
Patellar tendinosis showed higher optical density of COX-2 when 
compare with healthy patellar tendon. Independent t-test showed a 
significant difference of the optical density of COX-2 between patellar 
tendinosis and healthy patellar tendon (p <0.001) indicating a higher 




Figure 3. 22 Immunohistochemical stain for COX-2 
Representative pictures showing COX-2 expression in tendinosis patellar 
tendon (A) and (B) healthy patellar tendon. Immunohistochemical 
staining using monoclonal mouse anti-human COX-2 antibody. 
Haematoxyline was used as a counter stain. Magnification: 400X. 
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Figure 3.23 Percentage of TGFpl immunopositive cells 
Blot plot showing percentage of TGppi immunopositive cells per 
viewing field of patellar tendinosis and healthy patellar tendon. Patellar 
tendinosis showed higher percentage of TGFpl immunopositive cells 
when compare with healthy patellar tendon. Independent t-test showed a 
significant difference of the percentage of TGFpl immunopositive cells 
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Figure 3.24 Expression level of TGFp1 
Blot plot showing optical density presenting expression level of TGppi 
per viewing field in patellar tendinosis and healthy patellar tendon. 
Patellar tendinosis showed higher optical density of TGppi when 
compare with healthy patellar tendon. Independent t-test showed a 
significant difference of the optical density of TGppi between patellar 
tendinosis and healthy patellar tendon (p <0.001) indicating a higher 
cellular expression of TGppi in patellar tendinosis. 
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Figure3.25 Immunohistochemical stain for TGFp1 
Representative pictures showing TGF|3l expression in tendinosis patellar 
tendon (A) and (B) healthy patellar tendon. Immunohistochemical 
staining using monoclonal chicken anti-human TGppi antibody. 
Haematoxyline was used as a counter stain. Magnification: 400X. 
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Figure 3.26 Percentage of PDGFBB immunopositive cells 
Blot plot showing percentage of P D G F B B immunopositive cells per 
viewing field of patellar tendinosis and healthy patellar tendon. 
Independent t-test showed no significant difference of the percentage of 
PDGFBB immunopositive cells between patellar tendinosis and healthy 
patellar tendon (p <0.001). 
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Figure 3.27 Expression level of PDGFBB 
Blot plot showing optical density presenting expression level of PDGFBB 
per viewing field in patellar tendinosis and healthy patellar tendon. 
Independent t-test showed no significant difference of the optical density 
of PDGFBB between patellar tendinosis and healthy patellar tendon (p 
<0 .001) indicating no difference of cellular expression of PDGFBB 
between patellar tendinosis and healthy controls. 
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Figure 3.28 Immunohistochemical stain for PDGFBB 
Representative pictures showing PDGFBB expression in tendinosis 
patellar tendon (A) and (B) healthy patellar tendon. 
Immunohistochemical staining using monoclonal goat anti-human 
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Figure 3.29 Percentage of PDGFRp immunopositive cells 
Blot plot showing percentage of PDGFRP immunopositive cells per 
viewing field of patellar tendinosis and healthy patellar tendon. Patellar 
tendinosis showed higher percentage of PDGFRP immunopositive cells 
when compare with healthy patellar tendon. Independent t-test showed a 
significant difference of the percentage of PDGFRp 1 immunopositive 
cells between patellar tendinosis and healthy patellar tendon (p <0.001). 
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Figure 3.30 Expression level of PDGFRp 
Blot plot showing optical density presenting expression level of 
PDGFRp per viewing field in patellar tendinosis and healthy patellar 
tendon. Patellar tendinosis showed higher optical density of PDGFRp 
when compare with healthy patellar tendon. Independent t -test showed a 
significant difference of the optical density of PDGFRp between patellar 
tendinosis and healthy patellar tendon (p <0.001) indicating a higher 
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Figure3.31 Immunohistochemical stain for PDGFRp 
The brown colour presented immunopositive stain with PDGFRp was 
localized in tenocytes of tendinosis patellar tendon section ( A: arrow). 
The expression level and percentage of immunopositive cells of PDGFRP 
were higher in tendinosis patellar tendon section (A) than in healthy 
patellar tendon section (B). The negative control was done by omitting 
the primary abtibody for PDGFRp (C: patellar tendinosis; D: healthy 
patellar tendon). Magnification: 400X. 
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Tendinosis Control P value 
N=ll N=12  
Total cell number per view 56.52±6.2 9.26±1.2 p<O.OQl* 
Proliferative Index 35.45±3.0 — 7.68±1.2 pcO.OoT^ 
Percentage of hsp47 immunopositive 46.12±4.63 14.86±3.14 p<0.001* 
cells  
Optical density of hsp47 0.09605±0.02658 0.Q3919±0.03161 "p<0.001* 
Optical density of procollagen type I 0.1208±0.04226 0.08915 ±0.04576 p=0.101 
Percentage of procollagen type I 39.36±4.69 19.32±2.34 pcO.OOl* 
immunopositive cells  
Percentage of M M P l immunopositive 47.00 ±2.40 17.70±2.59 pcO.OOl* 
cells  
Optical density of M M P l — 0.1441 ±0.02378 "Q.07481 ±0.03982 p<O.Ql* 
Percentage of TIMPl immunopositive 3.36±0.92 23.48 ±4.30 p<0.001* 
cells  
Optical density of TIMPl 0.01760±0.01288_ 0.03819±0.01914 p<0.001* 
Percentage of COX-2 immunopositive 73.13±16.17 25.15±20.75pcO.OOl* 
cells  
Optical density of COX-2 0.1473±0.02254 "a05464±0.03243~ pcO.OOl* 
Percentage of TGFpl immunopositive 56.40±16.97 23.06±13.22p<0.001* 
cells  
Optical density of TGFpl 0.1106±0.01860 "o.Q5263±0.02667 pcO.OOl* 
Percentage of PDGFBB immunopositive 18.92±1.68 15.35±1.25 p=0.099 
cells  
Optical density of PDGFBB ~ 0.03928±0.01114 "a^l47±0.0927Q" p=0.084 
Percentage of PDGFRp immunopositive 66.88±3.0 23.95±4.1 p<0.001* 
cells  
Optical density of PDGFRp 0.06973 ±0.01238 0.02704 ±0.01485 p<0.001 * 
Table3.2: Summary of semi -quantitation of immunohistometry 
Table showing the results of the statistic analysis of semi -quantitation of 
immunohistometry. Data are presented as mean ± Stander Deviation. * 
marks statistical significance for independent t test, statistical significant 
level is set at p< 0.01. 
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Figure 3.32 Fluorescence in situ gelatin zymography of 
tendon samples at beginning of incubation. 
Representative pictures showing on zero -hour time point of 
incubation, there was no any dark zones could be seen under 
fluorescence microscopy on both patellar tendinosis tissue (A) and 
in healthy patellar tendon tissue (B). Magnification: lOOX. 
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Figure 3.33 Fluorescence in situ gelatin zymography of tendon 
samples after two hours of incubation. 
Representative pictures showing after two hours of incubation, there 
was the presence of dark zones indicating gelatinolytic activity in 
patellar tendinosis tissue (A), contrasted to no dark zones seen in 
healthy patellar tendon (B). Magnification: lOOX. 
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Figure 3.34 Fluorescence in situ gelatin zymography of tendon 
samples after twenty-four hours of incubation. 
Representative pictures s howing after twenty-four hours of 
incubation, more dark zones could be seen in patellar tendinosis 
tissues (A), and still there was no dark zone present in healthy 
controls (B). Magnification: lOOX. 
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Figure 3.35 In situ gelatin zymography of tendon samples 
showing proteolytic areas under light microscopy 
Representative pictures showing gelatinolytic activity mainly resided in 
the areas with disorganization and loosening of collagen fibrils in patellar 





Figure 3.36 Negative control of fluorescence in situ gelatin 
zymography incubated with EDTA. 
Represen ta t ive pic tures s h o w i n g the sec t ions were incubated with 
mc ta l lopro tcascs inhibitor ( E D T A ) s h o w e d no dark zones presented in both 
patellar t endinos is tissue (A) and heal thy control (B). Magni f ica t ion : lOOX. 
CHAPTER FOUR 
DISCUSSION 
Table 3.3 一 The association between the proteolytic activities and 
patellar tendinosis  
Healthy Tendinosis Total 
patellar tendon patellar tendon  
No proteolytic 12 0 12 
activities 
Highly increased 0 11 11 
proteolytic activities  
T o ^ 12 n 23 
Fisher's Exact Test demonstrated that the association between patellar tendinosis and 
increased proteolytic activities was statistically significant (pcO.OOl) 
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4 DISCUSSION 
4.1 DIAGNOSIS O F P A T E L L A R TENDINOSIS 
The clinical symptom of anterior knee pain associated with tenderness at the 
proximal part of the patellar tendon is very common in orthopaedic sports medicine. 
However, previous studies have often suffered from a lack of diagnostic criteria for 
this chronic patellar tendon disorder due to the confusing clinical nomenclature. That 
lead to relatively little is known about the etiology and pathogenesis as well as the 
natural history of this problem. Therefore, the efficacy of available treatments on this 
disease is vague (Khan et al., 1999). 
Several authors have proposed various classifications and grading systems for 
this condition, but each has its limitations (Uhthoff et al., 1991; Khan et al., 1999). In 
the current study, we had established the diagnostic criteria for patellar tendinosis 
based on both clinical manifestations and histopathological examinations. By using 
these criteria, the patients with patellar tendinosis had been recruited and then the 
surgical specimens had been characterized in this study. 
On clinical aspects, all recruited patients had been suffered from long-
standing, activities related pain, swelling and tenderness around the proximal part of 
the patellar tendon. They all failed to improve with various types of conservative 
treatments. Surgical treatment was indicated after verification by ultrasound or M R L 
All patients appeared the characteristic sonographic hypoechogenic regions under US 
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or high signal intensity on T1 and T2 weighted images under M R I around proximal 
part of the patellar tendon respectively. 
On histopathological aspects, the surgical findings were correlated to 
symptoms and US or M R I findings. The tissues from each of this group of patients 
consistently showed hypercellularity, hypervascularity, lack of inflammatory cells 
infiltrates and disorganization and loosening of collagen fibrils as well as an increase 
of glycosaminoglycan content in the extracellular matrix, revealed by H & E staining, 
Sanfranine O staining and polarization microscopy examination. 
The results showed that the surgical specimens, from patients in this study 
with anterior knee pain associated with tenderness at the proximal part of the patellar 
tendon, have the homogenous histopathological changes similar to that of patellar 
tendinosis reported in the literatures (Khan et al., 1998). There are no evidences 
representing paratendinitis or truly intratendinous tendinitis in this group of patients. 
Besides, current samples of patellar tendinosis exhibited histopathological alterations 
similar to those previously described in Achilles tendinosis (Astrom et al., 1995; Rolf 
et al., 1997)，and rotator cuff tendinosis (Riley et al., 1994) as well as tendinosis of 
elbow (Kraushaar et al., 1999). These findings may thus contribute to further 
understand the pathogenesis of tendinosis as a common process in tendons at various 
anatomical positions. 
Although the possible predisposed factors vary from patient to patients, 
certainly this group of patients are not heterogeneous at least on histopathological 
perspective, and facilitated to further characterization on its histopathological 
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alterations. In this study, hypercellularity, disorganization and loosening of collagen 
fibrils, local inflammatory response and spectrum of cytokines expression have been 
further characterized, to elaborate the pathogenesis of patellar tendinosis. The results 
are discussed as follows. 
4.2 C H A R A C T E R I Z A T I O N ON H Y P E R C E L L U L A R I T Y IN P A T E L L A R 
TENDINOSIS 
The current study is the first of its kind to objectively demonstrate 
hypercellularity associated with an increased cell proliferation in human patellar 
tendinosis. The P C N A staining unambiguously indicates the presence of a large 
number of clustering proliferating cells. This indicates that tendinosis, at least during 
the period of sampling, which was more than six months after onset of subjective 
symptoms, is an on-going process, and further increase in cellularity can be 
anticipated. It may be argued that cells behave differently in a pathologic 
microenvironment such as in tendinosis, but our cell culture experiments clearly 
supported the increased proliferation capability of the tendinosis cells. The 
transformed properties of the cells are thus inheritable and are not dependent on local 
environmental factors in the tendon, since the primary culture free from a diseased 
micromilleu also behaved similarly (Pau, M.Phil thesis. 2000). 
The "tendinosis cells，，appear to have different shape and size compared with 
the tenocytes observed in the healthy controls. Since these “tendinosis cells" also 
express procollagen type I，which had been demonstrated in the current study. And in 
vitro studies, the extracted cells from patellar tendinosis tissues were stained with 
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fibroblast markers (Pau, M.Phil thesis. 2000). So, they may possibly originate from 
tenocytes. Hypercellularity occurs in the early healing phase of any tendon injury, 
where the proliferating tenocytes retain the fibroblastic appearance and inflammatory 
cells are abundant (Nagata et al., 1996; Satoh et al., 1996). Tenocyte is the reparative 
cell in tendon injury which when activated behaves like a modified form of 
fibroblast. This cell is the source of collagen production, protein mediators of repair 
and matrix proteoglycans as well as some cytokines, such as PDGFBB, TGF|3l et, al 
(O'Brien et al., 1997; Chan et al., 1998). Bound normally within a dense, linear 
orientated collagenous matrix, these cells take on a distinct biological behavior and a 
fibroproductive phenotypic expression dictated in part by their deformation and cell 
shape (Amadio et al., 1992) 
Is tendinosis caused by an injury? Repair of soft tissue injury is defined as 
replacement of lost cells and extracellular matrices with new cells and matrices. 
(Amadio et al., 1992) However, a severely disrupted extracellular matrix 
accompanies the obvious cell number increment in patellar tendinosis. Cellular 
responses after tendon injury may include an extrinsic response with proliferation 
and bridging of the injury by the epitenon cells (Banes et al” 1988; Woo et al” 1995) 
or an intrinsic healing response as the result of endotendon fibroblast repairing 
(Russell et al., 1989). Epitenocytes are actively involved in macrotraumatic lesions, 
but the role of endotenocyte remains controversial (Russell et al., 1989; Woo et al., 
1995). 
Tendinosis is clinically regarded as a "chronic" condition (Astrom et al., 
1995; Rolf et al., 19997; Khan et al., 1999). Chronic injury is characterized by slow 
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insidious onset, implying an antecedent subthreshold spectrum of structural damage 
leading to crisis episode that is heralded by pain and/or signs of inflammation lasting 
months to years distinguished by persistent symptoms without resolution (Lundborg 
et al., 1978). As clearly shown from this study the cells are not in a silent end stage 
of a degenerative disorder but rather involved in a highly active process. This 
suggestion is supported also by our findings of an increased expression of MMPl, 
and an increased proteoglycan deposition (Movin et al, 1997; Rolf et al, 1997; 
Movin et al., 1998). Degeneration describes a change in tissue from a higher to a 
lower or less functionally active form causing cell atrophy and degenerative change 
(Lundborg et al., 1978). The patellar tendinosis cells show signs of the opposite, i.e. 
an increased cellular activity 
The- expansion of cell population in fibrous tissues may call on the 
disintegration of collagenous matrix to free out the space, as seen from the 
characteristic gross collagen disturbances, thus raising the speculation that tendinosis 
might partly be rooted from alterations in cellular activities. It is thus very likely that 
an expansion of cell number will be at a cost of the fibrous structure of the tendon. 
The collagen fibres were indeed disrupted and disorganized in all the present 
samples. 
In conclusion, this study clearly shows that the observed hypercellularity in 
patellar tendinosis is caused by increased cell proliferation. 
4.3 CHARACTERIZATION ON COLLAGEN DISTURBANCE 
97 
The current study is the first of its kind reporting an increased hsp47 
expression and postulating the possible cause of severe collagen disturbances in 
human patellar tendinosis. Apart from the presence of stressful factors in tendinosis, 
the results indicate that an imbalance of collagen synthesis and degradation may be 
involved in patellar tendinosis, leading to a disrupted collagen matrix. 
Heat shock protein 47 is an inducible intracellular protein in response to 
stress. Under stressful conditions, the maintenance of protein folding and hence 
proper protein functions is hampered, heat shock proteins including hsp47 serve to 
stabilize protein folding and sustain their functions. Although hsp47 is also expressed 
in some normal situations such as cell cycle regulation and cell differentiation, 
augmented expression of this protein is generally induced by a number of metabolic 
stresses such as heat shock, ischaemia and injury (Jarvinen et al., 1997) and in a 
number of pathological conditions such as arthritis and fibrosis. Increased specific 
binding capacity of the patients' sera to hsp47-like proteins has been demonstrated in 
rheumatoid arthritis suggesting the involvement of hsp47 in cartilage destruction of 
the disease (Hattori et al., 1998). In an animal model for osteoarthritis, the m R N A 
expression of hsp47 in chondrocytes was also induced and associated with trauma 
and inflammation (Takahashi et al., 1997). In a number of fibrotic diseases such as 
interstitial fibrosis in unilaterally obstructed kidneys in rat (Moriyama et al., 1998), 
nephrectomized progressive glomerulosclerosis (Sunamoto et al., 1998), and 
spontaneous nephropathy in old F344 rats (Razzaque et al., 1998)，immunoreactivity 
of hsp47 was also augmented. Other stressful factors such as malignant 
transformation (Nagata et al., 1986) and exposure to transforming growth factor beta 
1 (TGF-Pl) (Yamamura et al., 1998) also associate with hsp47 expression. Most of 
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these pathological situations involve varying degree of matrix disorganization similar 
to what has been observed in tendinosis, and the role of increased expression of 
hsp47 can be regarded as a protective mechanism to safeguard the production of 
procollagen in response to a need to repair the collagenous matrix (Masuda et aL, 
1994; Kawada et al., 1996; Razzaque et aL, 1998). Over-expression of hsp47 can 
thus be regarded as a sign of both the presence of stress factors and a demand of 
collagen synthesis (Nagata et al., 1996; Nagata et al” 1998). 
In the current study, although the increased percentage of cells synthesizing 
procollagen type I in tendinosis suggests a tendency to produce collagen in order to 
recuperate the loss in the disrupted collagen matrix (Russell et al 1989), the level of 
procollagen type I immunopositivity failed to increase correspondingly. This 
implied that the production of procollagen type I may be limited by unknown factors, 
even though there was a stimulation of collagen synthesis. As the expression of 
hsp47 remained high in tendinosis tissues, there may be some stressful factors 
persistent in tendinosis tissues that continued to exert influences to the diseased 
tendon. 
The observation of limited collagen synthesis is consistent with the typical 
histopathological characteristics of tendinosis tissue with disrupted extracellular 
matrix and decreased collagen stainability (Movin et al., 1997; Movin et al” 1998; 
Rolf et aL, 1998). This may be attributed to increase collagen matrix degradation, as 
demonstrated by the augmented expression of MMPl, one of the matrix 
metalloproteinases, and increased proteolytic activity in situ, as well as the decreased 
expression of TIMPl, one of the tissue inhibitors of metalloproteinases (TIMPs) 
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regulating the activity of MMPs. A number of connective tissue disorders (Peters et 
al” 1997; Palombo et al” 1999), inflammatory diseases (Kieseier et al” 1999)，as 
well as neoplasm (Powell et al., 1996)，are found to be associated with an imbalance 
of M M P s and TIMPs in favour of enhanced matrix degradation. It is thus possible 
, that the pathological changes of relative levels of M M P l and TIMPl, as well as the 
augmented proteolytic activity in tendinosis favour matrix degradation and result in a 
disrupted extracellular matrix. On the other hand, since M M P l and TIMPl play an 
important role in wound healing especially in remodeling of extracellular matrix 
(Parks et al., 1998)，it is possible that tendinosis manifests as a tendon healing 
disorder. 
4.4 CHARACTERIZATION ON I N F L A M M A T O R Y RESPONSE IN 
P A T E L L A R TENDINOSIS � 
The expression of COX-2 was higher in patellar tendinosis tissues as 
compared to healthy controls. The results implied that elevated levels of COX-2 were 
involved in the development of the pathological conditions of patellar tendinosis. 
Since COX-2 is the rate-limiting enzyme for the synthesis of pro-inflammatory 
prostaglandins, when COX-2 increases, the production of pro-inflammatory 
prostaglandins such as PGE2 increase (Seitbet et al., 1997). In vitro studies from our 
research group had demonstrated that the production of PGE2 by tendinosis 
fibroblasts was also significantly higher than that by healthy tendon fibroblasts. 
PGE2 is a potent vaso-depressor that increases blood flow to the inflamed site and 
enhances edema. It lowers the pain threshold by sensitizing the peripheral terminals 
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of primary afferent nociceptor (Zhang et al., 1997; Vane et al., 1998). Thus, it is 
possible that the clinical signs of tendinosis, manifested as swelling and activity-
related pain, may be related to increased production of PGE2. However, since all 
tendinosis patients in this study have taken non-steroidal anti-inflammatory drugs 
(NSAID) as treatment and the conditions were not improved, other mediators for 
edema and pain may be involved in addition to the elevated prostaglandin 
production. 
COX-2 is an inducible enzyme that responds quickly to inflammatory 
cytokines, and its expression level is subsided when the inflammatory response is 
resolved (Vane et al., 1998). Despite the lack of inflammatory signs, we still found a 
detectable expression of COX-2 in healthy patellar tendons from A C L reconstruction 
surgery. It may be explained by stimulatory factors originated from A C L tears. The 
presence of induction signals such as wounds is necessary for the sustained 
expression of COX-2. In patellar tendinosis, inflammatory infiltration was not 
observed but C O X expression was high, some stimulatory signals for COX-2 
induction must be present. Since COX-2 can be induced by TGppi (Vane et al., 
1998)，we speculated that sustained COX-2 expression in patellar tendinosis tissues 
was associated with increased TGppi levels, which had been demonstrated in 
current studies. 
The elevation of expression level of COX-2 and TGppi can be considered as 
"signs" of inflammatory events, but the apparent absence of inflammatory cells in the 
tendinosis tissues put doubts on the existence of inflammation. The present study 
may provide a possible explanation since PGE2 and TGFp also possess anti-
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inflammatory actions. Despite its ability to regulate early inflammatory response, 
TGpp exerts anti-proliferative activated leukocytes and effectively dampen immune 
and inflammatory pathways (Benson, 1998; Wahl et a 1.，1999). Similarly, PGE2 is a 
potent inhibitor of neutrophil and monocyte in spite of its vaso-regulatory activities 
(Wu etal., 1996; Zhang et al, 1997). A sustained elevation of TGpp expression and 
PGE2 production may thus negatively regulate inflammatory response. 
All tendinosis cases received more than six months of non-operative 
management including physiotherapeutic modalities after manifestation of 
symptoms, and surgical operation is performed when these treatments are 
insufficient, with M R I and ultrasound imaging indicating the development of 
tendinosis. It is thus not certain whether inflammatory responses have been involved 
in early stages of tendinosis, or a normal inflammatory response should have died out 
in the period of non-operative treatment. Therefore, we cannot rule out an early 
inflammatory phase or other inflammatory mediators involving in the development 
of patellar tendinosis. 
4.5 THE EXPRESSION OF GROWTH FACTORS IN PATELLAR 
TENDINOSIS 
The current study also is the first of its kind to examine the expression profile 
of growth factors in patellar tendinosis compared to healthy patellar tendon. Two 
growth factors，TGppi, PDGFBB, which are the most common growth factors of 
interest in regulating tendon metabolism and healing process (Chan et al., 1998), 
were detected immunohistochemically. The results showed that the expression level 
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of TGFpl was significantly higher in patellar tendinosis than in healthy controls. 
There was no significant difference of the expression level of PDGFBB between 
patellar tendinosis and healthy controls. The results implied that the alteration of 
expression spectrum of growth factors might be involved in the pathogenesis of 
patellar tendinosis. 
Growth factors play an important role in the pathogenesis of many diseases, 
such as tumor, immunologic disorders, osteoarthritis et al (Leadbetter, 1992; Chan et 
al., 1998; Stone et al., 1999). The increased expression of TGF(3l and tumor 
necrosis factors has been associated with the tumor development (Benson, 1998). It 
has been demonstrated that the fibrosis diseases were associated with increased 
expression of PDGFBB (Smits et al., 1992). In patellar tendinosis, we detected an 
increased expression level of TGFpl. That might indicate the increased expression of 
TGFpl associated with the development of tendinosis. TGF(3l is a cytokine that have 
broad spectrum of actions, including tissue repair, stimulating proliferation, pro-
inflammatory response and resolution of inflammatory events (Krummel et al., 1988; 
Benson, 1998). In soft tissue healing, TGppi is able to induce proteoglycan synthesis 
(Robbins 1997) and suppress proteoglycan degradation (Mango et al., 1994), 
resulting in a deposition of proteoglycans. It had also been demonstrated that TGppi 
could upregulate PDGFRP subunits (Oates 1995), then leading to promote cell 
proliferation. TGppi can also upregulate M M P l (Benson, 1998) expression, and is 
involved in adhesion formation in tendon (Abraham et al., 2000). In inflammatory 
response, TGFpl is up regulated locally during inflammation. TGppi promotes 
inflammatory responses in early phase including leukocyte recruitment, adhesion, 
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secretion and activation of M M P s (Chang et al., 1997); but its roles reverse to 
suppress these events to resolve inflammation and mediate repair at a later stage 
(Chang et al., 1997). Thus the pathological changes in tendinosis including increased 
cellularity, augmented colllagenoysis and proteoglycan deposition, which had been 
demonstrated in this study, may be related to increased levels of TGFpi. 
P D G F B B has been demonstrated to promote proliferation and matrix 
remodeling and maturation during the tendon healing process (Barrett et aL, 1996; 
Chan et al., 1998). However, the expression of PDGFBB was shown to have no 
difference between patellar tendinosis and healthy controls, although tendinosis 
resembles as a non-healing status. It maybe there is some factors involved in 
tendinosis to suppress the expression of these growth factors, or it may be due to the 
interactions among cytokines. Complex interplay exists among TGF(3l, PDGFBB in 
soft tissues since one can affect another activity by altering ligand availability or 
receptor levels (Leadbetter, 1992; Benson, 1998). Because of the complicated 
cellular and molecular interactions, it is difficult to predict the in vivo effects of a 
given cytokine. 
Growth factors or cytokines exert their biological effects on cells by binding 
to specific cell-surface, high-affinity receptors (Chan et aL, 1998). The changes at the 
receptor level of cytokines can also result in the alteration of the pathophysical 
functions. In current study, we had demonstrated that the expression level of the 
platelet-derived growth factor receptor beta (PDGFR(3) was significantly higher in 
patellar tendinosis than in healthy controls. The results implied that these were not 
only a change of expression of growth factors, but also an alteration of expression on 
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receptor level of cytokines. Since PDGFBB activation on PDGFRp is a well-known 
trigger of fibroblastic cell proliferation (Harts et al., 1988; Smits et al, 1992). 
Hypercellularity in patellar tendinosis, which caused by increased cell proliferation, 
may associate with an increased expression of PDGFRP. On the other hand, 
PDGFRp can be up regulated by TGppi(Gates et al., 1995; Benson, 1998). 
Therefore, the increased expression of TGppi can increase the expression of 
PDGFRP, leading to promotion of cell proliferation as well as other biological 
effects. 
4.6 P R O P O S E D P A T H O G E N E S I S F O R P A T E L L A R T E N D I N O S I S 
Several authors discussed in detail the pathophysiology of tendinosis and 
provided some theoretical models to describe the histopathologic entities of affected 
tendons (Lozsa, 1997; Khan et al., 1999). However, one of the greatest problems in 
our understanding of the pathogenesis or development and pathophysiology of 
tendinosis has been the lack of experimental and clinical data on the development of 
the tendinosis. A significant amount of scientific data is available on the healing 
response of acutely traumatized tendon and ligament, “the process of wound 
healing", while information on tendinosis has been lagging because of the inherent 
non-operative nature of the early stages of these conditions and the lack of an animal 
model (Backman et al” 1991; Messner et al., 1999). 
Several theories of the pathogenesis of patellar tendinosis have been proposed 
including overuse, degeneration, decreases blood supply et al (Leadbetter, 1992; 
Lozsa, 1997; Khan et al., 1999). However, the results from current study put doubt 
105 
on it. Although it has been said that this chronic patellar tendon disorder mostly 
relates to sport-induced injures and overuse, however, it also could be found in 
recreational athletes or in patients with no relation to vigorous physical activities or 
"disuse". Like the patients in this study, only two of eleven patients had high level of 
activities, others just have recreational level of activities or even no vigorous 
physical activities (why overuse injury?). In addition, the further characterization on 
patellar tendinosis tissues showed hypercellularity was caused by an increased cell 
proliferation implied that there is an increased cellular activity in patellar tendinosis. 
Combination of our findings of an increased percentage of cell synthesizing 
procollagen type I，an increased expression of MMPl, and an increased proteoglycan 
deposition in tendinosis, the cells in patellar tendinosis are not in a silent end stage of 
a degenerative disorder but rather involved in a highly active process (why 
degeneration?). Furthermore, our histopathologic studies on patellar tendinosis 
showed there was an increased cell proliferation of endothelial cells of vessels within 
the tendons. In addition, the results from our research group showed that the 
condition medium from patellar tendinosis fibroblasts cell culture has the 
angiogenesic effects. The results implied that the tendinosis cells could release some 
mediators to promote the ingrowth of vessels, leading to hypervascullarity seen in 
tendinosis. Such possible mediators may be TGF|3l as well as PDGFBB. SO the 
theoretical models, which decreased blood, supply lead to hypoxia intratendiously 
causing downstream degenerative changes within tendon, are not supported by our 
experimental findings (Backman et al” 1991). 
Once the tendon are injured either by intrinsic factors such as vascular 
vulnerability, limited cell function potential, aging, hormonal, autoimmune etc; or by 
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extrinsic factors such as continued self-abuse, improper training, harsh environment, 
joint instability, extrinsic pressure etc, the injured tendon go through the healing 
response to repair the injuries. Normal tendon healing process involves an organized 
series of processes including inflammatory phase, proliferative phase and maturative 
phase, with participation of extrinsic and intrinsic cells, extracellular matrix 
components and regulation by biological factors such as growth factors (Lundborg et 
al., 1978; Amadio 1992). In the phase of inflammation, extrinsic inflammatory cells 
secrete chemotactic, mitogenic and angiogenic factors, such as fibronectin and 
macrophage-derived growth factor, initiating subsequent healing stages in the injured 
tissue. Inflammation lasts two to five days and is followed by the proliferative phase 
and the phase of tissue maturation and remodeling. The inflammation may persist 
longer, becoming self-perpetuating and involve surrounding structures. In the second 
stage of healing, fibroblasts begin proliferating to produce collagen and matrix 
proteoglycans. In this phase, these products are immature, lack of organization, and 
are therefore susceptible to destruction if some factors exit persistently, such as 
trauma, inflammation. Continuous deposition and degradation of collagen and matrix 
proteoglycans persists for a long period for remodeling. During these phases, growth 
factors also play an important role as their unique properties in (1) reducing 
inflammation, (2) stimulating cell proliferation and other cellular activities, (3) 
regulating deposition and degradation of collagen and matrix proteoglycans, (4) 
promoting functional restorations of the normal tissue structure. In the later phase of 
normal tendon healing, fibroblasts stop to proliferate and matrix deposition is 
gradually switched from proteoglycans to collagen (Kelly et al., 1984; Amadio et al., 
1992; Leadbetter et al.，1992; Chang et al., 1997; Chan et al., 1998). 
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According to our results of further characterization on patellar tendinosis 
tissues, patellar tendinosis remarkably resembles a poor healing response, and it 
seems to be a "halt" in the early phase of tendon healing, except for the absence of 
inflammatory response. Therefore, a delayed or non-healing status has been proposed 
to be one of pathogenesis of patellar tendinosis. Upon unknown stimulus, the tendon 
was injured and goes through healing repair processes. If the stimulus exist 
persistently or exceed the rate of repair, or the cell-matrix of tendon fail to adapt to 
excessive changes, tendinosis fibroblasts may respond abnormally to stimulation of 
wound healing, with the altered local release of cytokines, resulting in both autocrine 
and paracrine modulation of further cell activity and a non-healing status with 
progressive cell proliferation and matrix destruction. However, Why tendinosis 
fibroblasts respond abnormally to stimulation of wound healing is unknown. 
According to our findings, which there are the changes of cellular morphology and 
activity, the alterations of the expression of cytokines and its receptors such as 
TGppi and PDGFRP in patellar tendinosis, we speculate that there may be an 
occurrence of cell transformation in patellar tendinosis fibroblasts. 
4.7 LIMITATIONS OF THIS STUDY 
A weakness of this study is that the samples are collected at one point in time 
after more than six months of severe disabling symptoms. For obvious reasons, there 
are no studies assessing tendinosis tissues over time from early onset of symptoms. 
Before the surgery, all patients received different kinds of conservative modalities 
for several months, including physiotherapy, NSAIDs. Whether or how these 
interventions affect the nature history of patellar tendinosis is still unclear. 
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Another limitation of this study is the verification of the predisposed factors 
inducing patellar tendinosis among the patients. As the onset of symptoms was 
generally and vaguely described by all patients with tendinosis, patients could not tell 
exactly when the initiated episode was and what the causes were. However, 
clinically, it is unlikely that a partial rupture of the tendon precedes this condition in 
these patients, since it is most likely to involve a sudden onset of pain during activity. 
The techniques we used which is the semi-quantitative immnohistochemistry 
have their limitations on detection of protein expression. More quantitative, sensitive 
methods should certainly facilitate future studies. Nevertheless, the current study is 
the first study to systematically characterize the pathophysiology of patellar 
tendinosis on molecular level, it do afford more information on understanding of 
pathogenesis of patellar tendinosis, and facilitate ultimate clinical applications. 
4.8 F U T U R E STUDIES 
Future studies on patellar tendinosis should focus on both clinical and basic 
science aspects. On clinical aspects, a more conscientious classification scheme to 
define the clinical entities should be established, with universally accepted 
definitions and standardized diagnostic tests. For doing so, performing natural 
history and epidemiological studies on patellar tendinosis are crucial. It will provide 





Histopathological examination of patellar tendinosis tissues should be done 
whenever possible to provide precise information on the nature of patellar tendinosis. 
It would be helpful to create an appropriate patellar tendinosis animal model in order 
to study the failing healing response and to develop new therapeutic modalities. In 
the present study, the relationship among the alteration of expression spectrum of 
cytokines, the changes of cellular activity and the matrix destruction remain 
unknown. Future studies therefore should focus on what mechanism lead to these 
changes, e.g., whether there is an alteration of signaling pathway from the stimulus to 
the biosynthesis of different macromolecules such as cytokines or inflammatory 
mediators, whether there are gene mutations in tendinosis leading to the abnormal 
expression of macromolecules. 
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5 CONCLUSION: 
The current study is the first of its kind to further characterize the 
histopathologic alteration in patellar tendinosis with aspects of hypercellularity, 
collagen disturbances, and inflammatory response as well as expression of growth 
factors. By using established diagnostic criteria, we refined the recruitment of 
patients with patellar tendinosis indicated for surgery. The surgical samples were 
analyzed by using histology and immunohistochemistry to compare with healthy 
controls from A C L reconstruction patellar tendon graft. 
The histopathological studies showed the homogenous changes similar to that 
of patellar tendinosis reported in the literature and similar to that previously 
described in Tendo Achilles tendinosis, rotator cuff tendinosis as well as tendinosis 
of elbow. There is no evidence for paratendinitis or truly intratendinous tendinitis in 
patellar tendinosis. Our results indicated that tendinosis is more likely to be a 
common chronic tendon disorder at various anatomical positions with similar 
histopathological changes. 
PCNA staining showed that there was an increased cell proliferation in 
patellar tendinosis indicating hypercellularity, (a characteristic change in tendinosis), 
may be caused by increased cell proliferation. 
The present study demonstrates for the first time a significant increase in the 
expression of hsp47, suggesting that the stressful factors present in tendinosis and an 
increased need for collagen synthesis. But the increase of expression of procollagen 
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type I was not statistically significant in tendinosis tissues, indicating a disturbed 
collagen synthesis in patellar tendinosis. The study also demonstrated augmented 
extracellular matrix degradation in patellar tendinosis. The disorganization and 
loosening of collagen fibrils may be associated with increased collagen degradation, 
partly contributed by increased expression of M M P l and decreased expression of 
TIMPl. 
Although truly intratendinous tendinitis cannot be found in tendinosis, 
however, the expression of COX-2, one of inflammatory mediators was higher in 
patellar tendinosis tissues as compared to healthy controls. The results implied that 
elevated levels of COX-2 were involved in the development of the pathological 
condition of patellar tendinosis, and an early phase of inflammation in tendinosis 
could not be ruled out. 
The expression level of TGFpl and PDGFRP was significantly higher in 
patellar tendinosis than in healthy controls. There was no significant difference 
between the expression levels of PDGFBB. The results implied that the alteration in 
the expression of growth factors and its receptor might contribute to the 
histopathologic alterations in tendinosis. The change of growth factors expression 
might play an important role in the pathogenesis of tendinosis. 
According to current studies on histopathological changes, patellar tendinosis 
appears most likely to be a non-healing and on-going status, at least at the time of 
tissue sampling. The exact mechanism of development and the denouement of 
patellar tendinosis need further study. 
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